{"original_query": "What are some ways to overcome ethical challenges in xenotransplantation?", "input": "are some ways ethical challenges xenotransplantation", "output": {"sections": [{"title": "Background on Xenotransplantation", "tldr": "Xenotransplantation is the process of transplanting organs or tissues from animals to humans to address organ shortage. Ethical challenges arise from various concerns including animal welfare, infection risks, and complex consent issues. (LLM Memory)", "text": "\nXenotransplantation refers to the transplantation of living cells, tissues, or organs from one species to another, specifically from animals (typically pigs or non-human primates) to humans. This medical procedure has been developed as a potential solution to the critical shortage of human organs available for transplantation, with thousands of patients dying annually while waiting for compatible organs. The field has seen significant advancement through genetic engineering techniques that modify animal organs to reduce rejection by the human immune system. While offering potential solutions to organ scarcity, xenotransplantation presents multiple ethical challenges that must be addressed before widespread clinical application. These ethical concerns span from animal welfare considerations to potential zoonotic disease risks, patient consent complexities, religious and cultural objections, resource allocation questions, and the need for comprehensive regulatory frameworks. <Model name=\"Anthropic\" version=\"claude-3-7-sonnet-20250219\">", "citations": [], "table": null}, {"title": "Animal Welfare and Rights Concerns", "tldr": "Xenotransplantation raises fundamental ethical concerns about animal welfare and rights, as it requires genetically modifying animals and keeping them in artificial environments that restrict natural behaviors. These concerns include questions about the moral status of animals, whether humans have the right to use animals for human benefit, and the welfare conditions of animals bred specifically for organ harvesting. (11 sources)", "text": "\nAnimal welfare and rights concerns represent a significant ethical challenge in xenotransplantation, with many animal rights organizations explicitly opposing the use of animals for such research <Paper corpusId=\"258276646\" paperTitle=\"(Santos, 2023)\" isShortName></Paper>. A central ethical tension emerges from what some ethicists describe as an \"anthropocentric approach\" that prioritizes human interests over those of animals, contrasting with a more inclusive \"biocentric perspective\" that values all forms of life equally <Paper corpusId=\"267567406\" paperTitle=\"(Hawthorne, 2024)\" isShortName></Paper>. This fundamental tension raises questions about whether animals, like humans, have inherent rights to existence that should not be sacrificed to benefit humans <Paper corpusId=\"253286042\" paperTitle=\"(Oli et al., 2022)\" isShortName></Paper> <Paper corpusId=\"221306753\" paperTitle=\"(Cengiz et al., 2020)\" isShortName></Paper>.\n\nThe living conditions of animals bred for xenotransplantation present particular welfare concerns. These animals must be raised in pathogen-free environments that necessitate sterile, indoor housing rather than natural pasture habitats <Paper corpusId=\"276315377\" paperTitle=\"(Krebs et al., 2025)\" isShortName></Paper>. Such conditions severely restrict natural behaviors and social interactions, causing significant stress responses with various biological and physiological consequences <Paper corpusId=\"276315377\" paperTitle=\"(Krebs et al., 2025)\" isShortName></Paper>. The welfare of animals bred in laboratory conditions that differ significantly from their natural environments requires careful definition and monitoring <Paper corpusId=\"249734546\" paperTitle=\"(Boulet et al., 2022)\" isShortName></Paper>.\n\nThe ethical complexity increases when considering the genetic modification of animals for xenotransplantation. Creating human-pig chimeras containing human genes and cells evokes strong reactions from various perspectives <Paper corpusId=\"58644768\" paperTitle=\"(Casal et al., 2019)\" isShortName></Paper>. Some argue that such modifications represent a \"deep transgression of the natural order\" for theological, ecological, or dignity-related reasons <Paper corpusId=\"58644768\" paperTitle=\"(Casal et al., 2019)\" isShortName></Paper>. Specific concerns have been raised about human cells potentially populating animal brains or germlines, which might confer morally relevant human traits or lead to transmission of human genes if animals were accidentally released <Paper corpusId=\"58644768\" paperTitle=\"(Casal et al., 2019)\" isShortName></Paper>.\n\nAnother profound ethical issue concerns consent. While human-to-human transplantation typically involves informed consent from donors or their families, animals cannot provide consent for the use of their organs <Paper corpusId=\"267749482\" paperTitle=\"(Andrade et al., 2024)\" isShortName></Paper> <Paper corpusId=\"221862396\" paperTitle=\"(Rollin, 2020)\" isShortName></Paper> <Paper corpusId=\"255213612\" paperTitle=\"(Bobier et al., 2022)\" isShortName></Paper>. This raises questions about the ethical permissibility of using animals for human benefit without their consent, especially considering that pigs and non-human primates used in xenotransplantation are cognitively complex animals with capacity for significant suffering <Paper corpusId=\"276315377\" paperTitle=\"(Krebs et al., 2025)\" isShortName></Paper>.\n\nSome ethicists argue that discussion of animal ethics in xenotransplantation often falls short by making inappropriate comparisons to animal use for food or by focusing strictly on welfare without considering broader ethical questions <Paper corpusId=\"276315377\" paperTitle=\"(Krebs et al., 2025)\" isShortName></Paper>. The scale of animal use is also notable, encompassing not only pigs used directly for transplants but also those used in research to refine methods and justify human trials <Paper corpusId=\"276315377\" paperTitle=\"(Krebs et al., 2025)\" isShortName></Paper>.\n\nThe medical and scientific communities face the responsibility of providing sufficient information to enable informed public debate on these issues <Paper corpusId=\"28577007\" paperTitle=\"(Sim et al., 1999)\" isShortName></Paper>. Some researchers emphasize that potential risks and benefits to human and non-human animals should be thoroughly considered before proceeding with xenotransplantation <Paper corpusId=\"221306753\" paperTitle=\"(Cengiz et al., 2020)\" isShortName></Paper>. Others advocate exploring all feasible alternatives to increase organ supply before resorting to xenotransplantation, recognizing the moral distinction between imposing risks on others before or after exhausting alternative solutions <Paper corpusId=\"221306753\" paperTitle=\"(Cengiz et al., 2020)\" isShortName></Paper>.\n\nAs developments in xenotransplantation continue, finding an ethical balance between medical innovation and responsibility to both animals and humans remains a crucial challenge <Paper corpusId=\"267567406\" paperTitle=\"(Hawthorne, 2024)\" isShortName></Paper>, requiring comprehensive ethical consideration by all stakeholders, including the general public <Paper corpusId=\"276315377\" paperTitle=\"(Krebs et al., 2025)\" isShortName></Paper>.", "citations": [{"id": "(Santos, 2023)", "paper": {"corpus_id": 258276646, "title": "Kidney Xenotransplantation: Are We Ready for Prime Time?", "year": 2023, "venue": "Current Urology Reports", "authors": [{"name": "Rafael Miyashiro Dos Santos", "authorId": "2172088613"}], "n_citations": 4}, "snippets": ["Many animal rights organizations are against the use of animals for research, including xenotransplantation.\n\nOthers argue that scientists may disturb the fundamental nature of a species, despite the fact that selective breeding has caused more extensive modifications than the ten genetic alterations engineered for xenotransplantation (George, 2022).\n\nAs xenotransplant may lead to zoonotic diseases with public health implications, one of the most challenging aspects of its implementation is the possible requirement of life-long monitoring for patients and their close contacts [70]. This concern has some regulatory agencies, such as the Council of Europe Recommendations Rec (2003) 10 of the Committee of Ministers to Member States on xenotransplantation, Article 21, stating that patients may have to waiver some of their human rights for close follow-up and monitoring", ".individuals seeking xenotransplantation may resort to traveling to countries with looser policies for the life-saving procedure, imposing increased risks for zoonosis upon their return home where animal husbandry and organ screening regulations are more stringent (Jorqui-Azofra, 2020).\n\nMoreover, there are questions if a collective consent should be required prior to initiation of xenotransplant trials since this procedure may carry risks for a broader population beyond the patients participating in the study (Jorqui-Azofra, 2020)."], "score": 0.96435546875}, {"id": "(Hawthorne, 2024)", "paper": {"corpus_id": 267567406, "title": "Ethical and legislative advances in xenotransplantation for clinical translation: focusing on cardiac, kidney and islet cell xenotransplantation", "year": 2024, "venue": "Frontiers in Immunology", "authors": [{"name": "Wayne J. Hawthorne", "authorId": "2261459618"}], "n_citations": 14}, "snippets": ["One ethical concern intrinsic to xenotransplantation relates to the potential for the transmission of diseases from animals to humans, a phenomenon known as xenozoonosis. The concept of transmission although theoretical is not unfounded, as various pathogens, including retroviruses, have been identified in pigs could be potential threats in immunocompromised transplant recipients and then theoretically spread to direct close contacts and the broader community (24,(Groenendaal et al., 2023)", "The duty to protect the broader community and prevent the spread of theoretically potential infectious diseases must be weighed against the need to explore novel medical solutions to help these patients suffering from end stage organ failure and other diseases (Hawthorne et al., 2022)", "From a patient and community perspective it is therefore essential for the patients, their family and immediate direct contacts along with the community to understand that if there were in fact a positive case of transmission of a xenozoonosis into a xenotransplant patient that there may well be serious implications to all involved. These implications are potentially as severe as lifelong restriction and quarantine of the recipient and may extend to their direct close contacts (25).\n\nXenotransplantation challenges the traditional conceptual boundaries that separate humans from animals. It poses profound philosophical and ethical questions about the nature of different species and the moral obligation we owe to different species. As we engage in practices that involve genetic modification and the use of animals for human benefit, the ethical boundaries are changing with increasing pressure on ethics committees and legislators to keep track with the pace of change, and we have a moral imperative to ensure that we do keep pace and provide adequate oversight (6).\n\nSome ethicists argue that xenotransplantation exemplifies the Anthropocentric approach (38), emphasizing human interests over those of animals, while others advocate for a more inclusive biocentric perspective that values all forms of life equally (39). The challenge is to find a balance between medical innovation and ethical responsibility to both animal and man (6)."], "score": 0.99462890625}, {"id": "(Oli et al., 2022)", "paper": {"corpus_id": 253286042, "title": "Classic and Current Opinions in Human Organ and Tissue Transplantation", "year": 2022, "venue": "Cureus", "authors": [{"name": "A. Oli", "authorId": "6234364"}, {"name": "Adekunle Babajide Rowaiye", "authorId": "2148618005"}, {"name": "S. Adejumo", "authorId": "2189658445"}, {"name": "F. I. Anazodo", "authorId": "2189658242"}, {"name": "Rahnuma Ahmad", "authorId": "2054233390"}, {"name": "Susmita Sinha", "authorId": "46534705"}, {"name": "Mainul Haque", "authorId": "2061252439"}, {"name": "Nihad Adnan", "authorId": "6323392"}], "n_citations": 7}, "snippets": ["Another fundamental challenge facing xenograft is ethical issues. Three ethical issues quickly come to mind when we talk of xenotransplantation: animal rights (effects on the donor animal), human rights (the impact on the human population and the impact on the individual recipient), and interference with nature. An animal rights issue arises because animals, like humans, also have rights to existence and should not be sacrificed in favor of humans (Cengiz et al., 2020). Human rights regarding the recipient can quickly be cleared by obtaining the necessary informed consent. Still, the populace also needs authorization because of the possibility of transferring new pathogens from animal to human populations -a public health risk (Abouna, 2003). The ethical issue of interference with nature may not be so applied. It may be understandable that by interfering with nature, man can free himself from the extinction effects of some natural phenomena [28]."], "score": 0.98046875}, {"id": "(Cengiz et al., 2020)", "paper": {"corpus_id": 221306753, "title": "Ethical considerations in xenotransplantation: a review", "year": 2020, "venue": "Current Opinion in Organ Transplantation", "authors": [{"name": "N. Cengiz", "authorId": "1907504545"}, {"name": "C. Wareham", "authorId": "145619065"}], "n_citations": 15}, "snippets": ["Purpose of review The purpose of this review is to present and analyse recent literature on the patterns, trends, and developments of ethical considerations concerning xenotransplantation by appraising normative aspects within a coherent framework. Recent findings Developments within xenotransplantation may soon allow for pig-to-human xenotransplantation to take place. Ethical analysis of xenotransplantation commonly follows an anthropocentric cost\u2013benefit analysis, which may imprecisely measure costs. Xenotransplantation should not merely be approached from an anthropocentric perspective. Rather, the potential risks presented to human and nonhuman donors, recipients, and third parties should all be thoroughly considered. Summary The range of feasible alternatives to xenotransplantation to increase organ supply should be examined before resorting to xenotransplantation because of the moral distinction between imposing certain risks on others before, or after, alternative solutions have been exhausted."], "score": 0.0}, {"id": "(Krebs et al., 2025)", "paper": {"corpus_id": 276315377, "title": "Considering the Risks and Costs of Solid Organ Xenotransplantation", "year": 2025, "venue": "Advances in Biology", "authors": [{"name": "Catharine E. Krebs", "authorId": "4578479"}, {"name": "Janine McCarthy", "authorId": "145242705"}, {"name": "Kristie Sullivan", "authorId": "32700735"}, {"name": "James Craner", "authorId": "2345165491"}, {"name": "Brendan Parent", "authorId": "2243026320"}, {"name": "Ann Lam", "authorId": "2345168135"}], "n_citations": 1}, "snippets": ["There are myriad ethical issues related to nonhuman animals' use in xenotransplant research and practice, including their sentience, suffering, and moral status, but discussions fall short by making inappropriate comparisons to animal use for food or by focusing strictly on animal welfare. [12] ore comprehensive ethics considerations by all stakeholders, including the general public, are necessary to decide the societal acceptability and desirability of xenotransplantation research and commercialization.\n\nAs with animal agriculture, the large-scale farming of pigs for xenotransplantation requires animals to live truncated lives under unnatural conditions. Pathogen-free environments require excluding animals from their natural pasture habitat and raising them in sterile, indoor housing, which severely limits their natural range of animal behavior and social interactions. Captivity, isolation, handling, transport, and other standard conditions of modern pig farming cause significant stress responses in pigs, with a variety of biological and physiological consequences. [37] he number and type of animals at stake are not only the pigs used directly for each transplant, but also the pigs and primates used in research to refine xenotransplant methods and justify human recipient trials, as well as the animals used as feed. Furthermore, not every animal would be killed for their organs; some would be kept for breeding; and some would inevitably fail to meet the required criteria for organ viability, such as the absence of pathogens, and it is unlikely that these animals would be routed to environments in which they can flourish. Every pig and nonhuman primate used in these contexts is a cognitively complex animal with the capacity for significant suffering. [38]"], "score": 0.96533203125}, {"id": "(Boulet et al., 2022)", "paper": {"corpus_id": 249734546, "title": "Cardiac Xenotransplantation", "year": 2022, "venue": "JACC: Basic to Translational Science", "authors": [{"name": "J. Boulet", "authorId": "147033575"}, {"name": "J. Cunningham", "authorId": "12848802"}, {"name": "M. Mehra", "authorId": "1810556"}], "n_citations": 12}, "snippets": ["One major ethical consideration in XTx is the concern for animal rights and the anthropocentric view of putting humans above all other animal species. (Cengiz et al., 2020) The welfare of animals being bred in laboratories with living conditions that significantly differ from their usual environments will need to be defined. (1998) Other challenges include the fairness of resource allocation and distributive justice, in an era when there is already much confusion in patients with respect to the current organ allocation system.\n\nAnother major aspect will be appropriately educating clinicians and patients, particularly with respect to the challenge of obtaining well-informed consent in an area with a high degree of uncertainty. These considerable ethical, social, and legal challenges will require careful consideration and discourse in a manner concurrent with scientific advances in the field."], "score": 0.97607421875}, {"id": "(Casal et al., 2019)", "paper": {"corpus_id": 58644768, "title": "Human iPSC-Chimera Xenotransplantation and the Non-Identity Problem", "year": 2019, "venue": "Journal of Clinical Medicine", "authors": [{"name": "P. Casal", "authorId": "115920900"}, {"name": "Andrew J. Williams", "authorId": "1748359546"}], "n_citations": 5}, "snippets": ["In cases of xenotransplantation, when the donor and the recipient belong to different species, further issues arise, regarding (i) the unavoidable harms to the donor and (ii) the possible harms to the recipients. When the donor is a chimeric pig, designed to contain a percentage of human genes and cells, xenotransplantation provokes two opposing sets of reactions [5].\n\nFor some, the use of human-pig chimeras strengthens both recipient-based and donor-based objections, rendering xenotransplantation more objectionable or even impermissible. Many feel an aversion to such a deep transgression of the natural order, for reasons that may be theological, ecological, or involve human dignity, animal rights or fear of scientists yet again producing undesirable, unforeseen, and irreversible consequences. Others have more specific concerns. For example, the US National Institutes of Health suspended funding of their chimeric xenotransplantation program in 2015 over concerns about introducing human DNA into a member of another species, and particularly doing so at such an early developmental stage. As Carrie Wolinetz, Salz Institute's Associate Director for Science Policy, explains: 'people were concerned about human cells populating the brain of the animal or the germline of the animal' [6]. In the first case, the animal might acquire morally relevant human traits; in the second case, the animal might transmit human genes and traits to its offspring, for example, if accidentally released into the wild."], "score": 0.97314453125}, {"id": "(Andrade et al., 2024)", "paper": {"corpus_id": 267749482, "title": "Moral approval of xenotransplantation in Egypt: associations with religion, attitudes towards animals and demographic factors", "year": 2024, "venue": "BMC Medical Ethics", "authors": [{"name": "Gabriel Andrade", "authorId": "2247520816"}, {"name": "Eid Abohamza", "authorId": "1393191851"}, {"name": "Yasmeen G. Elsantil", "authorId": "120949403"}, {"name": "AlaaEldin Ayoub", "authorId": "2284669594"}, {"name": "Dalia Bedewy", "authorId": "7810347"}], "n_citations": 3}, "snippets": ["Other concerns are ethical. Xenotransplantation carries the potential risk of transmitting infectious diseases from animals to humans. Ethical concerns center on the precautionary principle, which suggests that xenotransplantation should not be pursued until the risks of zoonotic diseases are better understood and minimized (Fovargue et al., 2010). Likewise, the long-term health and safety of recipients of xenotransplants are still not fully known, which raises ethical issues regarding patient safety and the potential for unforeseen complications (Ravelingien, 2007). \n\nThe ethics of human-animal relations are also an issue. There are concerns about the conditions in which donor animals are raised and the potential for harm, suffering, and exploitation of these animals (Mani et al., 2003). As with animal experimentation, there is the ethical difficulty of consent (Daar, 1997). In human-to-human organ transplantation, informed consent is typically obtained from donors or their families. In xenotransplantation, there is no way to obtain informed consent from the donor animals, raising ethical questions about the use of animals for the benefit of humans without their consent (Rollin, 2020)(Bobier et al., 2022)."], "score": 0.98095703125}, {"id": "(Rollin, 2020)", "paper": {"corpus_id": 221862396, "title": "Ethical and Societal Issues Occasioned by Xenotransplantation", "year": 2020, "venue": "Animals", "authors": [{"name": "B. Rollin", "authorId": "6150203"}], "n_citations": 30}, "snippets": ["There are a variety of dangers associated with xenotransplantation, both for recipients and for the public at large. As yet, however, none of these projected dangers have come to pass, in part because there have been no successful xenotransplants. Governments have been extremely cautious about allowing unrestricted research into xenotransplantation to proceed, presumably because of societal hesitation regarding all aspects of biotechnology."], "score": 0.970703125}, {"id": "(Bobier et al., 2022)", "paper": {"corpus_id": 255213612, "title": "In defense of xenotransplantation research: Because of, not in spite of, animal welfare concerns", "year": 2022, "venue": "Xenotransplantation", "authors": [{"name": "C. Bobier", "authorId": "104028182"}, {"name": "D. Rodger", "authorId": "35586928"}, {"name": "Daniel J. Hurst", "authorId": "34438297"}, {"name": "Adam Omelianchuk", "authorId": "14931608"}], "n_citations": 4}, "snippets": ["It is envisioned that one day xenotransplantation will bring about a future where transplantable organs can be safely and efficiently grown in transgenic pigs to help meet the global organ shortage. While recent advances have brought this future closer, worries remain about whether it will be beneficial overall. The unique challenges and risks posed to humans that arise from transplanting across the species barrier, in addition to the costs borne by non\u2010human animals, has led some to question the value of xenotransplantation altogether. In response, we defend the value of xenotransplantation research, because it can satisfy stringent welfare conditions on the permissibility of animal research and use. Along the way, we respond to the alleged concerns, and conclude that they do not currently warrant a cessation or a curtailing of xenotransplantation research."], "score": 0.0}, {"id": "(Sim et al., 1999)", "paper": {"corpus_id": 28577007, "title": "Xenotransplantation: A potential solution to the critical organ donor shortage.", "year": 1999, "venue": "Canadian journal of gastroenterology = Journal canadien de gastroenterologie", "authors": [{"name": "K Howe Sim", "authorId": "2271839474"}, {"name": "Anton Marinov", "authorId": "2272149804"}, {"name": "Gary A Levy", "authorId": "2271801166"}], "n_citations": 24}, "snippets": ["Unlike other areas of clinical medicine, xenotransplantation raises a variety of ethical issues that have not been formally discussed or agreed upon in the public arena.The general public must play a role in defining ethical policies regarding xenotransplantation, and it is the duty of the medical and scientific communities to provide as much information as possible to them, so that public policies can be formulated in an informed manner.\n\nThe clinical application of xenotransplantation is predicated on the assumption that the use of animals in medical research and therapy is morally acceptable.Even if this debatable principle is accepted, the use of animals in xenotransplantation, particularly nonhuman primates, raises additional issues.That these animals may need to be genetically altered to overcome certain immunological obstacles further complicates their use as experimental subjects."], "score": 0.97900390625}], "table": null}, {"title": "Infection and Public Health Risks", "tldr": "Xenotransplantation poses potential public health risks through the transmission of animal pathogens to humans (xenozoonosis), which could spread beyond recipients to close contacts and the broader community. These concerns have led to calls for stringent monitoring protocols, specialized informed consent procedures, and comprehensive regulatory frameworks. (19 sources)", "text": "\nThe risk of disease transmission from animal organs to humans represents one of the most significant ethical challenges in xenotransplantation. The potential for xenozoonosis\u2014the transfer of infectious agents from animals to humans\u2014raises concerns that extend beyond individual patients to public health more broadly <Paper corpusId=\"253286042\" paperTitle=\"(Oli et al., 2022)\" isShortName></Paper> <Paper corpusId=\"267567406\" paperTitle=\"(Hawthorne, 2024)\" isShortName></Paper>. This concern has gained heightened attention following the COVID-19 pandemic, which illustrated the potential consequences of zoonotic diseases <Paper corpusId=\"253552364\" paperTitle=\"(George, 2022)\" isShortName></Paper>.\n\nPorcine Endogenous Retroviruses (PERVs) are particularly concerning as they are integrated into the pig genome and could potentially become active in human recipients, creating risks not only for the individual but potentially for their contacts and wider society <Paper corpusId=\"256590616\" paperTitle=\"(Galvao et al., 2023)\" isShortName></Paper> <Paper corpusId=\"219317659\" paperTitle=\"(Fishman, 2020)\" isShortName></Paper> <Paper corpusId=\"29444854\" paperTitle=\"(Groth, 2007)\" isShortName></Paper>. As one researcher notes, \"everyone could potentially benefit as an organ recipient, but at the same time may risk acquiring a xenogeneic infectious disease\" <Paper corpusId=\"221108043\" paperTitle=\"(Kogel et al., 2020)\" isShortName></Paper>. This represents a unique ethical dimension where individual treatment decisions could have broader societal impacts.\n\nThe management of these infection risks presents several complex ethical challenges. First, it may require lifelong surveillance of xenotransplant recipients and potentially their close contacts to detect any emerging infections early <Paper corpusId=\"256590616\" paperTitle=\"(Galvao et al., 2023)\" isShortName></Paper> <Paper corpusId=\"267567406\" paperTitle=\"(Hawthorne, 2024)\" isShortName></Paper>. This monitoring requirement raises serious questions about patient privacy, autonomy, and the potential restriction of civil liberties <Paper corpusId=\"276578858\" paperTitle=\"(Gordon et al., 2025)\" isShortName></Paper>. In extreme scenarios, infected recipients might face severe restrictions including potential quarantine measures that could extend to their close contacts <Paper corpusId=\"267567406\" paperTitle=\"(Hawthorne, 2024)\" isShortName></Paper>.\n\nInformed consent procedures for xenotransplantation must therefore address not only typical medical risks but also these broader public health considerations <Paper corpusId=\"248635370\" paperTitle=\"(Bayliss, 2022)\" isShortName></Paper>. Some have questioned whether informed consent should be obtained not only from the recipient but also from close contacts and medical personnel involved in the patient's care, given the potential for disease transmission <Paper corpusId=\"248635370\" paperTitle=\"(Bayliss, 2022)\" isShortName></Paper>. This represents a significant departure from standard informed consent practices in other medical procedures <Paper corpusId=\"276578858\" paperTitle=\"(Gordon et al., 2025)\" isShortName></Paper>.\n\nMore fundamentally, some ethicists argue that xenotransplantation raises questions about collective consent\u2014whether society at large should have input on proceeding with clinical trials that may carry population-level risks <Paper corpusId=\"258276646\" paperTitle=\"(Santos, 2023)\" isShortName></Paper>. This tension between individual autonomy and collective safety represents a central ethical dilemma, requiring balance between beneficence toward individual patients and protection of public health <Paper corpusId=\"256590616\" paperTitle=\"(Galvao et al., 2023)\" isShortName></Paper> <Paper corpusId=\"248323042\" paperTitle=\"(Entwistle et al., 2022)\" isShortName></Paper>.\n\nThe uncertainty surrounding these risks presents a unique challenge for medical technology assessment. Unlike conventional medical interventions that primarily affect individual patients, xenotransplantation potentially impacts public health more broadly, requiring proactive risk assessment and management at an early stage of technological development <Paper corpusId=\"34061863\" paperTitle=\"(Kaiser, 2004)\" isShortName></Paper>. The application of the precautionary principle suggests that xenotransplantation should not proceed until risks of zoonotic diseases are better understood and minimized <Paper corpusId=\"267749482\" paperTitle=\"(Andrade et al., 2024)\" isShortName></Paper> <Paper corpusId=\"5787929\" paperTitle=\"(Fovargue et al., 2010)\" isShortName></Paper>.\n\nWhile these infection risks remain largely theoretical\u2014with no major xenozoonotic outbreaks documented to date\u2014they have contributed to cautious regulatory approaches <Paper corpusId=\"221862396\" paperTitle=\"(Rollin, 2020)\" isShortName></Paper>. Governance challenges include determining appropriate oversight bodies for clinical trials, developing internationally compatible safety regulations, and establishing procedures for reporting and managing potential infections <Paper corpusId=\"260047382\" paperTitle=\"(Ku, 2004)\" isShortName></Paper>. These regulatory frameworks continue to evolve as the field advances <Paper corpusId=\"276324642\" paperTitle=\"(Spitz et al., 2025)\" isShortName></Paper>.\n\nSome observers have noted that infection risks might be managed through stringent breeding and screening protocols for source animals. Experts have identified hundreds of potential microorganisms and parasites of concern, many of which can be effectively eliminated through high biosecurity breeding programs <Paper corpusId=\"261120894\" paperTitle=\"(Groenendaal et al., 2023)\" isShortName></Paper>. However, the possibility of unknown pathogens remains a concern <Paper corpusId=\"267749482\" paperTitle=\"(Andrade et al., 2024)\" isShortName></Paper>. \n\nAddressing these infection risks requires balancing the urgent medical needs of patients awaiting organs against potential public health hazards, reflecting the fundamental ethical tension between advancing medical innovation and protecting population health <Paper corpusId=\"268361569\" paperTitle=\"(Hurst et al., 2024)\" isShortName></Paper>.", "citations": [{"id": "(Oli et al., 2022)", "paper": {"corpus_id": 253286042, "title": "Classic and Current Opinions in Human Organ and Tissue Transplantation", "year": 2022, "venue": "Cureus", "authors": [{"name": "A. Oli", "authorId": "6234364"}, {"name": "Adekunle Babajide Rowaiye", "authorId": "2148618005"}, {"name": "S. Adejumo", "authorId": "2189658445"}, {"name": "F. I. Anazodo", "authorId": "2189658242"}, {"name": "Rahnuma Ahmad", "authorId": "2054233390"}, {"name": "Susmita Sinha", "authorId": "46534705"}, {"name": "Mainul Haque", "authorId": "2061252439"}, {"name": "Nihad Adnan", "authorId": "6323392"}], "n_citations": 7}, "snippets": ["Another fundamental challenge facing xenograft is ethical issues. Three ethical issues quickly come to mind when we talk of xenotransplantation: animal rights (effects on the donor animal), human rights (the impact on the human population and the impact on the individual recipient), and interference with nature. An animal rights issue arises because animals, like humans, also have rights to existence and should not be sacrificed in favor of humans (Cengiz et al., 2020). Human rights regarding the recipient can quickly be cleared by obtaining the necessary informed consent. Still, the populace also needs authorization because of the possibility of transferring new pathogens from animal to human populations -a public health risk (Abouna, 2003). The ethical issue of interference with nature may not be so applied. It may be understandable that by interfering with nature, man can free himself from the extinction effects of some natural phenomena [28]."], "score": 0.98046875}, {"id": "(Hawthorne, 2024)", "paper": {"corpus_id": 267567406, "title": "Ethical and legislative advances in xenotransplantation for clinical translation: focusing on cardiac, kidney and islet cell xenotransplantation", "year": 2024, "venue": "Frontiers in Immunology", "authors": [{"name": "Wayne J. Hawthorne", "authorId": "2261459618"}], "n_citations": 14}, "snippets": ["One ethical concern intrinsic to xenotransplantation relates to the potential for the transmission of diseases from animals to humans, a phenomenon known as xenozoonosis. The concept of transmission although theoretical is not unfounded, as various pathogens, including retroviruses, have been identified in pigs could be potential threats in immunocompromised transplant recipients and then theoretically spread to direct close contacts and the broader community (24,(Groenendaal et al., 2023)", "The duty to protect the broader community and prevent the spread of theoretically potential infectious diseases must be weighed against the need to explore novel medical solutions to help these patients suffering from end stage organ failure and other diseases (Hawthorne et al., 2022)", "From a patient and community perspective it is therefore essential for the patients, their family and immediate direct contacts along with the community to understand that if there were in fact a positive case of transmission of a xenozoonosis into a xenotransplant patient that there may well be serious implications to all involved. These implications are potentially as severe as lifelong restriction and quarantine of the recipient and may extend to their direct close contacts (25).\n\nXenotransplantation challenges the traditional conceptual boundaries that separate humans from animals. It poses profound philosophical and ethical questions about the nature of different species and the moral obligation we owe to different species. As we engage in practices that involve genetic modification and the use of animals for human benefit, the ethical boundaries are changing with increasing pressure on ethics committees and legislators to keep track with the pace of change, and we have a moral imperative to ensure that we do keep pace and provide adequate oversight (6).\n\nSome ethicists argue that xenotransplantation exemplifies the Anthropocentric approach (38), emphasizing human interests over those of animals, while others advocate for a more inclusive biocentric perspective that values all forms of life equally (39). The challenge is to find a balance between medical innovation and ethical responsibility to both animal and man (6)."], "score": 0.99462890625}, {"id": "(George, 2022)", "paper": {"corpus_id": 253552364, "title": "Ethics, virtues and xenotransplantation", "year": 2022, "venue": "Perfusion", "authors": [{"name": "A. George", "authorId": "145179807"}], "n_citations": 10}, "snippets": ["Some of the major ethical issues in xenotransplantation are shown in Table 1. These include the risk of porcine-derived infectious agents causing disease in humans; awareness of the risk of zoonotic disease has been heightened by the COVID-19 pandemic. Other issues relate to the impact on the patient, the animal donors, identity and also issues relating to the allocation of organs and whether this is a resource effective solution to health challenges."], "score": 0.966796875}, {"id": "(Galvao et al., 2023)", "paper": {"corpus_id": 256590616, "title": "Bioethics and xenotransplantation from pig to human", "year": 2023, "venue": "Clinics", "authors": [{"name": "F. Galv\u00e3o", "authorId": "3202809"}, {"name": "Max B P Grinberg", "authorId": "2170702301"}], "n_citations": 2}, "snippets": ["Clinical application of innovation such as xenotransplantation raises questions concerning the balance between beneficence, individual autonomy and the recognition of possible damage to society and the environment. (Entwistle et al., 2022)(Silverman et al., 2022) The problems of autonomy in xenotransplantation are related to the difficulty of composing the free and informed consent form, since the risks and benefits for the recipient, given the complexity of the situation, are still unknown. Furthermore, some of the greatest risks of this procedure, zoonosis, is associated with the possibility of its success. Therefore, the recipient's notion of being able to withdraw from participating in the research at any time must be very well clarified before proceeding with the xenotransplantation, if there is a predictable chance of survival for a long period. (Entwistle et al., 2022)(Silverman et al., 2022) he risk of xenotransplant recipients contracting and transmitting Porcine Endogenous Retroviruses (PERV) infections is another bioethical issue that represents a potential public health problem because could cause a pandemic. This xenozoonosis or xenosis would be hazardous not only to the recipient but also to their contacts who would not even be aware of this situation. (Fishman, 2020)(Nellore et al., 2022)  recipients and their contacts probably will need lifelong surveillance to detect and treat any unexpected disease early and protect society as a whole. (Fishman, 2020)(Nellore et al., 2022) he appropriate care of the swine that will be a donor in the xenotransplantation is another important bioethical issue."], "score": 0.94091796875}, {"id": "(Fishman, 2020)", "paper": {"corpus_id": 219317659, "title": "Prevention of infection in xenotransplantation: Designated pathogen\u2010free swine in the safety equation", "year": 2020, "venue": "Xenotransplantation", "authors": [{"name": "J. Fishman", "authorId": "27553961"}], "n_citations": 45}, "snippets": ["Post\u2010transplantation infections are common. In immunosuppressed human xenograft recipients, infection is most likely to be due to the same pathogens seen in human allotransplantation. However, organisms derived from swine and transmitted with xenografts have the potential to cause novel infections in xenograft recipients. The specific organisms likely to cause infection or \"xenosis\" are unknown but are postulated to be like those causing infection in allograft recipients. On this basis, theoretical exclusion criteria have been developed to guide the development of source animal herds. Herds developed based on the exclusion of potential human pathogens have been termed \"designated pathogen\u2010free\" (DPF). Lists of potential pathogens will require revision with changing epidemiology of infection in swine worldwide and clinical experience. Development of new microbiological assays is required both for animal screening and in clinical diagnosis should infections occur. Genetic modifications of swine have the potential to eliminate certain infectious agents such as the porcine endogenous retrovirus; infectious complications of such modifications have not been observed. Unexpected, off target effects of genetic modifications require further study. Monitoring for infection in asymptomatic recipients is important to define infectious risks which are unknown in the absence of clinical trials data. Advanced microbiological techniques may be applied to diagnose and prevent infection in xenograft recipients."], "score": 0.0}, {"id": "(Groth, 2007)", "paper": {"corpus_id": 29444854, "title": "The potential advantages of transplanting organs from pig to man: A transplant Surgeon's view", "year": 2007, "venue": "Indian Journal of Urology", "authors": [{"name": "C. Groth", "authorId": "89217942"}], "n_citations": 17}, "snippets": ["There are several ethical issues pertaining to clinical xenotransplantation. One such issue concerns defining the harm/benefit ratio in the context of the initial clinical attempts. It might also be difficult to institute an appropriate informed-consent procedure. The fact that the patients will have to be monitored for possible infectious diseases for an extended time, possibly for life, is another ethical concern.\n\nMoreover, there are a number of ethical issues with regards to society at large. The public health hazard posed by the possible transmission and activation of PERV created considerable public concern a few years ago. The public debate that took place also generated some emotionally colored skepticism towards xenotransplantation, in which it was argued that \"transplantation from animal to man will violate the order of nature\". Other objections were with regard to the safety of the future recipients: \"xenotransplantation will constitute experimentation on sick human beings\"."], "score": 0.95947265625}, {"id": "(Kogel et al., 2020)", "paper": {"corpus_id": 221108043, "title": "\u201cXenotransplantation challenges us as a society\u201d", "year": 2020, "venue": "EMBO Reports", "authors": [{"name": "Johannes K\u00f6gel", "authorId": "144208416"}, {"name": "G. Marckmann", "authorId": "2065192923"}], "n_citations": 19}, "snippets": ["While these advances in XT provide hope for patients with irreversible organ failure, they also raise ethical and philosophical issues: Is it ethically acceptable to breed animals and use them as an organic spare parts stock? What does it mean anthropologically for patients to live with an animal organ or animal tissue? How shall we balance the potential benefits and risks of XT therapies, given that everyone could potentially benefit as an organ recipient, but at the same time may risk acquiring a xenogeneic infectious disease?"], "score": 0.962890625}, {"id": "(Gordon et al., 2025)", "paper": {"corpus_id": 276578858, "title": "Patients\u2019 Information Needs for Informed Consent to Participate in First\u2010in\u2010Human Pig Kidney Xenotransplant Clinical Trials: A Mixed Methods Study", "year": 2025, "venue": "Xenotransplantation", "authors": [{"name": "Elisa J. Gordon", "authorId": "2185546879"}, {"name": "Mickael K. Gusmano", "authorId": "2258689847"}, {"name": "Jessica Gacki-Smith", "authorId": "1399002102"}, {"name": "Hannah L Brooks", "authorId": "2344060875"}, {"name": "Margaret M Matthews", "authorId": "2344072682"}, {"name": "Dahlya Manning", "authorId": "2344068356"}, {"name": "Joseph Leventhal", "authorId": "2344060667"}, {"name": "K. Maschke", "authorId": "4295444"}], "n_citations": 0}, "snippets": ["The unknown potential to transmit known and unknown diseases from the pig organ to human recipient [16,17] elevates the risk profile of first-in-human pig kidney xenotransplant trials.\n\nMagnifying these challenges is that few, if any, treatment alternatives for patients with end-stage kidney disease exist, which can render patients vulnerable and undermine voluntary decision-making [12,13]. Such vulnerability commonly occurs among patients undergoing innovative surgical procedures for which alternative standard treatments are either ineffective or nonexistent [21].\n\nThe ethical challenges to informed consent comprise a component of translational research that requires resolution. Current federal regulations (i.e., the National Organ Transplant Act of 1984) lack guidance on informed consent for xenotransplant clinical trials [22]. Organ Procurement and Transplant Network policies only pertain to human organs. Thus, policies on information disclosure may not translate to the xenotransplant context."], "score": 0.96435546875}, {"id": "(Bayliss, 2022)", "paper": {"corpus_id": 248635370, "title": "Practical ethical concerns in allocation of pig kidneys to humans", "year": 2022, "venue": "Clinical Kidney Journal", "authors": [{"name": "G. Bayliss", "authorId": "3035167"}], "n_citations": 7}, "snippets": ["Initial concerns centered on whether animal-to-human transplants violate the laws of nature and whether it is wrong to sacrifice animals as organ donors to humans. Some feared social injustice by lopsided distribution of scarce resources to a few at the expense of broader basic medical care for all. Critics wondered whether xenotransplantation would endanger public health (Vanderpool, 1998). Other pressing questions touched on prerequisites for clinical trials: identifying acceptable risk-benefit thresholds and clinically defining success (extra days versus extra weeks or months of life, for example). Some questioned whether informed consent should be obtained from close contacts of the patient and medical personnel involved in the recipient's care, given concerns about zoonotic infection. It was argued that informed consent from recipients should include a broader set of risks including public attention, risk of transmitting disease and isolation. A final set of questions touched on who is responsible for oversight of clinical trials in xenotransplantation (local hospital review boards, national committees, or some combination)?"], "score": 0.96044921875}, {"id": "(Santos, 2023)", "paper": {"corpus_id": 258276646, "title": "Kidney Xenotransplantation: Are We Ready for Prime Time?", "year": 2023, "venue": "Current Urology Reports", "authors": [{"name": "Rafael Miyashiro Dos Santos", "authorId": "2172088613"}], "n_citations": 4}, "snippets": ["Many animal rights organizations are against the use of animals for research, including xenotransplantation.\n\nOthers argue that scientists may disturb the fundamental nature of a species, despite the fact that selective breeding has caused more extensive modifications than the ten genetic alterations engineered for xenotransplantation (George, 2022).\n\nAs xenotransplant may lead to zoonotic diseases with public health implications, one of the most challenging aspects of its implementation is the possible requirement of life-long monitoring for patients and their close contacts [70]. This concern has some regulatory agencies, such as the Council of Europe Recommendations Rec (2003) 10 of the Committee of Ministers to Member States on xenotransplantation, Article 21, stating that patients may have to waiver some of their human rights for close follow-up and monitoring", ".individuals seeking xenotransplantation may resort to traveling to countries with looser policies for the life-saving procedure, imposing increased risks for zoonosis upon their return home where animal husbandry and organ screening regulations are more stringent (Jorqui-Azofra, 2020).\n\nMoreover, there are questions if a collective consent should be required prior to initiation of xenotransplant trials since this procedure may carry risks for a broader population beyond the patients participating in the study (Jorqui-Azofra, 2020)."], "score": 0.96435546875}, {"id": "(Entwistle et al., 2022)", "paper": {"corpus_id": 248323042, "title": "Clinical xenotransplantation seems close: Ethical issues persist.", "year": 2022, "venue": "Artificial Organs", "authors": [{"name": "J. Entwistle", "authorId": "145855510"}, {"name": "R. Sade", "authorId": "37121104"}, {"name": "D. Drake", "authorId": "1978696"}], "n_citations": 16}, "snippets": ["Scientific barriers that have prevented successful xenotransplantation are being breached, yet many ethical issues remain. Some are broad issues that accompany the adoption of novel and expensive technologies, and some are unique to xenotransplantation. Major ethical questions include areas such as: viral transmission; zoonoses and lifetime surveillance; interfering with nature; efficacy, access, and expense; treatment of animals; regulation and oversight."], "score": 0.0}, {"id": "(Kaiser, 2004)", "paper": {"corpus_id": 34061863, "title": "Xenotransplantation: Ethical considerations based on human and societal perspectives", "year": 2004, "venue": "", "authors": [{"name": "M. Kaiser", "authorId": "39600443"}], "n_citations": 9}, "snippets": ["Xenotransplantation marks a qualitatively new challenge in medical technology assessment. The reasons for this claim are twofold: (i) in contrast to more traditional medical interventions, xenotransplantation involves risks not only to the patient, but also to larger segments of society, thus to public health in general. (ii) while most medical technologies demand assessment and risk-management at the time when the technology is sufficiently developed to be put into practice, xenotransplantation demands pro-active action at a very early stage of development. A particular challenge for any assessment of xenotransplantation is the inclusion of a satisfactory approach to the ethical issues involved."], "score": 0.98681640625}, {"id": "(Andrade et al., 2024)", "paper": {"corpus_id": 267749482, "title": "Moral approval of xenotransplantation in Egypt: associations with religion, attitudes towards animals and demographic factors", "year": 2024, "venue": "BMC Medical Ethics", "authors": [{"name": "Gabriel Andrade", "authorId": "2247520816"}, {"name": "Eid Abohamza", "authorId": "1393191851"}, {"name": "Yasmeen G. Elsantil", "authorId": "120949403"}, {"name": "AlaaEldin Ayoub", "authorId": "2284669594"}, {"name": "Dalia Bedewy", "authorId": "7810347"}], "n_citations": 3}, "snippets": ["Other concerns are ethical. Xenotransplantation carries the potential risk of transmitting infectious diseases from animals to humans. Ethical concerns center on the precautionary principle, which suggests that xenotransplantation should not be pursued until the risks of zoonotic diseases are better understood and minimized (Fovargue et al., 2010). Likewise, the long-term health and safety of recipients of xenotransplants are still not fully known, which raises ethical issues regarding patient safety and the potential for unforeseen complications (Ravelingien, 2007). \n\nThe ethics of human-animal relations are also an issue. There are concerns about the conditions in which donor animals are raised and the potential for harm, suffering, and exploitation of these animals (Mani et al., 2003). As with animal experimentation, there is the ethical difficulty of consent (Daar, 1997). In human-to-human organ transplantation, informed consent is typically obtained from donors or their families. In xenotransplantation, there is no way to obtain informed consent from the donor animals, raising ethical questions about the use of animals for the benefit of humans without their consent (Rollin, 2020)(Bobier et al., 2022)."], "score": 0.98095703125}, {"id": "(Fovargue et al., 2010)", "paper": {"corpus_id": 5787929, "title": "When should precaution prevail? Interests in (public) health, the risk of harm and xenotransplantation.", "year": 2010, "venue": "Medical Law Review", "authors": [{"name": "S. Fovargue", "authorId": "8410312"}, {"name": "S. Ost", "authorId": "7911746"}], "n_citations": 13}, "snippets": ["Xenotransplantation is an example of a developing biotechnology which highlights three differing interests in the health of the public; a specific interest in enhancing the health of individuals who require a particular procedure or treatment, a wider interest in protecting the health of us all by avoiding introducing biotechnologies which risk the health of the public, and a public interest in advancing medical knowledge and treatment. Here we explore how matters of private benefit and public risk can be appropriately reconciled and consider whether ideas of public health should take a more central role when deciding whether clinical xenotransplantation should proceed. The risks of xenotransplantation are not certain but the nature of the harm to individual and public health could be severe. The concept of risk is central to our analysis as xenotransplantation threatens potential future harm as well as possible benefit. We argue that it is sometimes legally and ethically necessary for the state to act in advance to protect the health of the public, and that xenotransplantation is such a case. In reaching this conclusion we adopt a precautionary approach; an approach which we modify by Mill\u2019s harm principle."], "score": 0.0}, {"id": "(Rollin, 2020)", "paper": {"corpus_id": 221862396, "title": "Ethical and Societal Issues Occasioned by Xenotransplantation", "year": 2020, "venue": "Animals", "authors": [{"name": "B. Rollin", "authorId": "6150203"}], "n_citations": 30}, "snippets": ["There are a variety of dangers associated with xenotransplantation, both for recipients and for the public at large. As yet, however, none of these projected dangers have come to pass, in part because there have been no successful xenotransplants. Governments have been extremely cautious about allowing unrestricted research into xenotransplantation to proceed, presumably because of societal hesitation regarding all aspects of biotechnology."], "score": 0.970703125}, {"id": "(Ku, 2004)", "paper": {"corpus_id": 260047382, "title": "Bioethical Issues in Xenotransplantation", "year": 2004, "venue": "Korean Journal of Medical Ethics", "authors": [{"name": "In-Hoe Ku", "authorId": "2085756759"}], "n_citations": 0}, "snippets": ["The transplantation of animal tissue and organs (xenotransplantation) is touted as one of the future options for transplantation medicine. This technology implies many unsolved practical and ethical problems.\nThe article summarizes those issues in xenotransplantation which require international efforts with special emphasis on safety regulations to prevent the transfer of pathogens from source animals to humans.\nThe most important result is the call for international guidelines, norms for reporting and compatible information technology. Means of risk assessment, risk management and risk prevention are necessary as public health tools to reduce or eliminate the risk of infection.\nThese are questions raised by patient monitoring and the implementation of archives, for example, or the economic aspects of xenotransplantation and the question of who is to bear the costs for international initiatives and public health safety mechanisms.\nThe article discusses the medical and ethical problems involved in weighing chances and risks are classified and discussed."], "score": 0.984375}, {"id": "(Spitz et al., 2025)", "paper": {"corpus_id": 276324642, "title": "Changes and Future Directions in Liver Transplantation in the United States", "year": 2025, "venue": "Livers", "authors": [{"name": "Francis Spitz", "authorId": "2345228645"}, {"name": "S. Dharmayan", "authorId": "65961700"}, {"name": "Jason Mial-Anthony", "authorId": "2322553670"}, {"name": "Abiha Abdullah", "authorId": "2345690409"}, {"name": "Charbel Elias", "authorId": "2322556382"}, {"name": "Godwin Packiaraj", "authorId": "2291656855"}, {"name": "Sabin Subedi", "authorId": "2345230818"}, {"name": "Michele Molinari", "authorId": "2256333628"}], "n_citations": 0}, "snippets": ["However, several challenges remain before xenotransplantation can become a routine clinical practice. Concerns about zoonotic disease transmission, long-term immunological compatibility, and ethical questions surrounding the use of animal organs in humans must be addressed. Regulatory frameworks are still developing, and more data are needed to assess the long-term viability and safety of xenotransplanted organs."], "score": 0.94140625}, {"id": "(Groenendaal et al., 2023)", "paper": {"corpus_id": 261120894, "title": "Expert opinion on the identification, risk assessment, and mitigation of microorganisms and parasites relevant to xenotransplantation products from pigs", "year": 2023, "venue": "Xenotransplantation", "authors": [{"name": "H. Groenendaal", "authorId": "50054678"}, {"name": "S. Costard", "authorId": "4359323"}, {"name": "Reid Ballard", "authorId": "2233455087"}, {"name": "S. Bienhoff", "authorId": "4754553"}, {"name": "Diana C Challen", "authorId": "2233455611"}, {"name": "Brandon J Dominguez", "authorId": "2233457269"}, {"name": "Douglas R Kern", "authorId": "40019097"}, {"name": "Dan Miller", "authorId": "46948900"}, {"name": "J. Noordergraaf", "authorId": "14938679"}, {"name": "L. Rudenko", "authorId": "143642795"}, {"name": "H. Schuurman", "authorId": "143715061"}, {"name": "T. Spizzo", "authorId": "24886585"}, {"name": "Matthew J. Sturos", "authorId": "15305216"}, {"name": "Bill Zollers", "authorId": "2233455589"}, {"name": "J. Fishman", "authorId": "27553961"}], "n_citations": 8}, "snippets": ["Xenotransplantation has the potential to address shortages of organs available for clinical transplantation, but concerns exist regarding potential risks posed by porcine microorganisms and parasites (MP) to the health of human recipients. In this study, a risk\u2010based framework was developed, and expert opinion was elicited to evaluate porcine MP based on swine exposure and risk to human health. Experts identified 255 MP to include in the risk assessment. These were rated by experts for five criteria regarding potential swine exposure in the USA and human health risks. MP were subsequently categorized into three risk mitigation groups according to pre\u2010defined rules: disqualifying porcine MP (due to their pathogenic potential, n = 130); non\u2010disqualifying porcine MP (still relevant to consider for biosecurity or monitoring efforts, n = 40); and alert/watch list (not reported in the USA or MP not in swine, n = 85). Most disqualifying (n = 126) and non\u2010disqualifying (n = 36) porcine MP can effectively be eliminated with high biosecurity programs. This approach supports surveillance and risk mitigation strategies for porcine MP in swine produced for xenotransplantation, such as documentation of freedom from porcine MP, or use of porcine MP screening, monitoring, or elimination options. To the authors\u2019 knowledge, this is the first effort to comprehensively identify all relevant porcine MP systematically and transparently evaluate the risk of infection of both donor animals and immunosuppressed human recipients, and the potential health impacts for immunosuppressed human recipients from infected xenotransplantation products from pigs."], "score": 0.0}, {"id": "(Hurst et al., 2024)", "paper": {"corpus_id": 268361569, "title": "Close contacts of xenograft recipients: Ethical considerations due to risk of xenozoonosis", "year": 2024, "venue": "Xenotransplantation", "authors": [{"name": "D. Hurst", "authorId": "2261600572"}, {"name": "L. Padilla", "authorId": "2266377005"}, {"name": "Daniel Rodger", "authorId": "2261607893"}, {"name": "Tamar Schiff", "authorId": "2250659270"}, {"name": "David K. C. Cooper", "authorId": "2184230422"}], "n_citations": 7}, "snippets": ["Ethical issues with clinical xenotransplantation have been described for decades, largely centering on animal welfare, the risks posed to the recipient, and public health risks posed by potential spread of xenozoonosis."], "score": 0.96826171875}], "table": null}, {"title": "Patient Consent and Autonomy Challenges", "tldr": "Xenotransplantation raises unique informed consent challenges including lifelong monitoring requirements, potential restrictions on civil liberties, and the need to consider risks that extend beyond the individual patient to close contacts and society at large. (14 sources)", "text": "\nXenotransplantation presents complex challenges regarding patient consent and autonomy that go beyond typical medical procedures. The consent process for xenotransplantation is complicated by the uncertainty of risks and benefits, making it difficult for patients to make fully informed decisions <Paper corpusId=\"256590616\" paperTitle=\"(Galvao et al., 2023)\" isShortName></Paper>. This uncertainty is particularly problematic because some of the greatest risks, such as zoonotic disease transmission, are associated with the procedure's success rather than its failure <Paper corpusId=\"256590616\" paperTitle=\"(Galvao et al., 2023)\" isShortName></Paper> <Paper corpusId=\"219317659\" paperTitle=\"(Fishman, 2020)\" isShortName></Paper>.\n\nA key consent challenge concerns the lifelong surveillance that recipients and possibly their close contacts may require to detect and address potential infections early <Paper corpusId=\"256590616\" paperTitle=\"(Galvao et al., 2023)\" isShortName></Paper> <Paper corpusId=\"219317659\" paperTitle=\"(Fishman, 2020)\" isShortName></Paper> <Paper corpusId=\"250989911\" paperTitle=\"(Nellore et al., 2022)\" isShortName></Paper>. This monitoring requirement raises significant concerns about patient privacy and autonomy <Paper corpusId=\"258276646\" paperTitle=\"(Santos, 2023)\" isShortName></Paper> <Paper corpusId=\"265121285\" paperTitle=\"(Thom et al., 2023)\" isShortName></Paper>. In extreme cases, infected recipients might face severe restrictions including quarantine measures that could extend to their close contacts <Paper corpusId=\"267567406\" paperTitle=\"(Hawthorne, 2024)\" isShortName></Paper>. Some regulatory frameworks, such as the Council of Europe Recommendations, have gone so far as to suggest that patients may need to waive certain human rights to facilitate necessary follow-up and monitoring <Paper corpusId=\"258276646\" paperTitle=\"(Santos, 2023)\" isShortName></Paper>.\n\nThe question of who should provide consent is also complicated in xenotransplantation. Some ethicists have proposed that informed consent should be obtained not only from recipients but also from their close contacts and medical personnel, given their potential exposure to zoonotic risks <Paper corpusId=\"248635370\" paperTitle=\"(Bayliss, 2022)\" isShortName></Paper>. More fundamentally, some argue that xenotransplantation raises questions about collective consent\u2014whether society at large should have input on clinical trials that carry population-level risks <Paper corpusId=\"258276646\" paperTitle=\"(Santos, 2023)\" isShortName></Paper>.\n\nThe consent process for xenotransplantation must address a broader set of risks compared to conventional procedures, including potential public attention, disease transmission, and isolation <Paper corpusId=\"248635370\" paperTitle=\"(Bayliss, 2022)\" isShortName></Paper>. This expanded informed consent should be a deliberative process occurring over several days, with participation by representatives from clinical ethics committees <Paper corpusId=\"252874917\" paperTitle=\"(Silverman et al., 2022)\" isShortName></Paper>.\n\nSpecial consent challenges arise in emergency situations. For patients with acute liver failure who arrive unconscious, the standard emergency treatment framework\u2014which doesn't require informed consent\u2014may conflict with the experimental nature of xenotransplantation procedures <Paper corpusId=\"247027354\" paperTitle=\"(Cross-Najafi et al., 2022)\" isShortName></Paper> <Paper corpusId=\"219330997\" paperTitle=\"(Schuurman et al., 2020)\" isShortName></Paper> <Paper corpusId=\"244428525\" paperTitle=\"(Hurst et al., 2021)\" isShortName></Paper>. In such cases, clinicians must navigate difficult decisions about proceeding with xenotransplantation using consent from family members or ethics committees <Paper corpusId=\"247027354\" paperTitle=\"(Cross-Najafi et al., 2022)\" isShortName></Paper>.\n\nPatient vulnerability presents another significant challenge. Patients with end-stage organ failure often have few or no treatment alternatives, which can undermine voluntary decision-making and render them vulnerable to accepting higher risks <Paper corpusId=\"276578858\" paperTitle=\"(Gordon et al., 2025)\" isShortName></Paper>. This vulnerability is common among patients considering innovative surgical procedures when standard treatments are ineffective or unavailable <Paper corpusId=\"276578858\" paperTitle=\"(Gordon et al., 2025)\" isShortName></Paper>.\n\nCurrent regulatory frameworks provide limited guidance on informed consent for xenotransplantation clinical trials. The National Organ Transplant Act of 1984 lacks specific guidance, and Organ Procurement and Transplant Network policies only apply to human organs <Paper corpusId=\"276578858\" paperTitle=\"(Gordon et al., 2025)\" isShortName></Paper>. This regulatory gap underscores the need for comprehensive consent frameworks specific to xenotransplantation.\n\nPatient selection for xenotransplantation trials raises additional ethical questions about justice and beneficence. Current recommendations often prioritize critically ill patients who have exhausted other options, but this approach has been criticized for potentially unfavorable risk-benefit ratios, particularly for patients with complex medical conditions <Paper corpusId=\"276610974\" paperTitle=\"(Shirini et al., 2025)\" isShortName></Paper>. Some ethicists argue that psychosocial criteria should be used not to exclude patients but to identify those requiring additional support <Paper corpusId=\"252874917\" paperTitle=\"(Silverman et al., 2022)\" isShortName></Paper>.\n\nPublic perception and emotional reactions to xenotransplantation further complicate the consent process. Arguments that xenotransplantation \"will violate the order of nature\" or constitutes \"experimentation on sick human beings\" reflect deeper societal concerns that may influence patient decision-making <Paper corpusId=\"29444854\" paperTitle=\"(Groth, 2007)\" isShortName></Paper>. Addressing these concerns requires proactive public engagement to build trust and address normative judgments that affect societal acceptance of this emerging biotechnology <Paper corpusId=\"276610974\" paperTitle=\"(Shirini et al., 2025)\" isShortName></Paper>.", "citations": [{"id": "(Galvao et al., 2023)", "paper": {"corpus_id": 256590616, "title": "Bioethics and xenotransplantation from pig to human", "year": 2023, "venue": "Clinics", "authors": [{"name": "F. Galv\u00e3o", "authorId": "3202809"}, {"name": "Max B P Grinberg", "authorId": "2170702301"}], "n_citations": 2}, "snippets": ["Clinical application of innovation such as xenotransplantation raises questions concerning the balance between beneficence, individual autonomy and the recognition of possible damage to society and the environment. (Entwistle et al., 2022)(Silverman et al., 2022) The problems of autonomy in xenotransplantation are related to the difficulty of composing the free and informed consent form, since the risks and benefits for the recipient, given the complexity of the situation, are still unknown. Furthermore, some of the greatest risks of this procedure, zoonosis, is associated with the possibility of its success. Therefore, the recipient's notion of being able to withdraw from participating in the research at any time must be very well clarified before proceeding with the xenotransplantation, if there is a predictable chance of survival for a long period. (Entwistle et al., 2022)(Silverman et al., 2022) he risk of xenotransplant recipients contracting and transmitting Porcine Endogenous Retroviruses (PERV) infections is another bioethical issue that represents a potential public health problem because could cause a pandemic. This xenozoonosis or xenosis would be hazardous not only to the recipient but also to their contacts who would not even be aware of this situation. (Fishman, 2020)(Nellore et al., 2022)  recipients and their contacts probably will need lifelong surveillance to detect and treat any unexpected disease early and protect society as a whole. (Fishman, 2020)(Nellore et al., 2022) he appropriate care of the swine that will be a donor in the xenotransplantation is another important bioethical issue."], "score": 0.94091796875}, {"id": "(Fishman, 2020)", "paper": {"corpus_id": 219317659, "title": "Prevention of infection in xenotransplantation: Designated pathogen\u2010free swine in the safety equation", "year": 2020, "venue": "Xenotransplantation", "authors": [{"name": "J. Fishman", "authorId": "27553961"}], "n_citations": 45}, "snippets": ["Post\u2010transplantation infections are common. In immunosuppressed human xenograft recipients, infection is most likely to be due to the same pathogens seen in human allotransplantation. However, organisms derived from swine and transmitted with xenografts have the potential to cause novel infections in xenograft recipients. The specific organisms likely to cause infection or \"xenosis\" are unknown but are postulated to be like those causing infection in allograft recipients. On this basis, theoretical exclusion criteria have been developed to guide the development of source animal herds. Herds developed based on the exclusion of potential human pathogens have been termed \"designated pathogen\u2010free\" (DPF). Lists of potential pathogens will require revision with changing epidemiology of infection in swine worldwide and clinical experience. Development of new microbiological assays is required both for animal screening and in clinical diagnosis should infections occur. Genetic modifications of swine have the potential to eliminate certain infectious agents such as the porcine endogenous retrovirus; infectious complications of such modifications have not been observed. Unexpected, off target effects of genetic modifications require further study. Monitoring for infection in asymptomatic recipients is important to define infectious risks which are unknown in the absence of clinical trials data. Advanced microbiological techniques may be applied to diagnose and prevent infection in xenograft recipients."], "score": 0.0}, {"id": "(Nellore et al., 2022)", "paper": {"corpus_id": 250989911, "title": "Moving xenotransplantation from bench to bedside: Managing infectious risk", "year": 2022, "venue": "Transplant Infectious Disease", "authors": [{"name": "A. Nellore", "authorId": "38159980"}, {"name": "Jeremey B. Walker", "authorId": "2110582276"}, {"name": "Mauricio Kahn", "authorId": "2114875371"}, {"name": "J. Fishman", "authorId": "27553961"}], "n_citations": 15}, "snippets": ["Xenotransplantation of organs from swine in immunosuppressed human recipients poses many of the same challenges of allotransplantation relative to the risk for infection, malignancy, or graft rejection in proportion to the degree of immunosuppression and epidemiologic exposures. The unique features of xenotransplantation from pigs relative to infectious risk center on the potential for unusual organisms derived from swine causing productive infection, \"xenosis\" or \"xenozoonosis,\" in the host. Based on experience in allotransplantation, the greatest hazard is due to viruses, due to the relative lack of information regarding the behavior of these potential pathogens in humans, the absence of validated serologic and molecular assays for swine\u2010derived pathogens, and uncertainty regarding the efficacy of therapeutic agents for these organisms. Other known, potential pathogens (i.e., bacteria, fungi, parasites) tend to be comparable to those of humans. Concerns remain for unknown organisms in swine that may replicate in immunosuppressed humans. Clinical trials of genetically modified organs sourced from swine in immunosuppressed humans with organ failure are under development. Such trials require informed consent regarding potential infectious risks to the recipient, determination of breeding characteristics of swine, assessments of potential risks to the public and healthcare providers, consideration of ethical issues posed by this novel therapy, and defined strategies to monitor and address infectious episodes that may be encountered by healthcare teams. Clinical trials in xenotransplantation will allow improved definition of potential infectious risks."], "score": 0.0}, {"id": "(Santos, 2023)", "paper": {"corpus_id": 258276646, "title": "Kidney Xenotransplantation: Are We Ready for Prime Time?", "year": 2023, "venue": "Current Urology Reports", "authors": [{"name": "Rafael Miyashiro Dos Santos", "authorId": "2172088613"}], "n_citations": 4}, "snippets": ["Many animal rights organizations are against the use of animals for research, including xenotransplantation.\n\nOthers argue that scientists may disturb the fundamental nature of a species, despite the fact that selective breeding has caused more extensive modifications than the ten genetic alterations engineered for xenotransplantation (George, 2022).\n\nAs xenotransplant may lead to zoonotic diseases with public health implications, one of the most challenging aspects of its implementation is the possible requirement of life-long monitoring for patients and their close contacts [70]. This concern has some regulatory agencies, such as the Council of Europe Recommendations Rec (2003) 10 of the Committee of Ministers to Member States on xenotransplantation, Article 21, stating that patients may have to waiver some of their human rights for close follow-up and monitoring", ".individuals seeking xenotransplantation may resort to traveling to countries with looser policies for the life-saving procedure, imposing increased risks for zoonosis upon their return home where animal husbandry and organ screening regulations are more stringent (Jorqui-Azofra, 2020).\n\nMoreover, there are questions if a collective consent should be required prior to initiation of xenotransplant trials since this procedure may carry risks for a broader population beyond the patients participating in the study (Jorqui-Azofra, 2020)."], "score": 0.96435546875}, {"id": "(Thom et al., 2023)", "paper": {"corpus_id": 265121285, "title": "Update on the ethical, legal and technical challenges of translating xenotransplantation", "year": 2023, "venue": "Journal of Medical Ethics", "authors": [{"name": "Rebecca Thom", "authorId": "2266152457"}, {"name": "D. Ayares", "authorId": "6281279"}, {"name": "David K. C. Cooper", "authorId": "2266161006"}, {"name": "John Dark", "authorId": "2299693157"}, {"name": "Sara Fovargue", "authorId": "2266152404"}, {"name": "Marie Fox", "authorId": "2266160103"}, {"name": "M. Gusmano", "authorId": "1662759024"}, {"name": "Jayme E Locke", "authorId": "2266159235"}, {"name": "Chris McGregor", "authorId": "2266151647"}, {"name": "Brendan Parent", "authorId": "34438103"}, {"name": "R. Ravanan", "authorId": "152158560"}, {"name": "D. Shaw", "authorId": "2258620328"}, {"name": "Anthony Dorling", "authorId": "2266152835"}, {"name": "Antonia J. Cronin", "authorId": "2253270241"}], "n_citations": 5}, "snippets": ["In addition to the major issues identified by Professor Gusmano and Professor Parent outlined in the previous section, during the roundtable discussion several additional ethical issues were proposed by our panel of experts and attendees. These included-ensuring equity of access to successful treatments, the burden of xenotransplantation monitoring requirements on patients, their close contacts and clinical personnel, and the need for cross border agreements to cover the prospect of recipients receiving initial treatment in one jurisdiction but moving to another."], "score": 0.98974609375}, {"id": "(Hawthorne, 2024)", "paper": {"corpus_id": 267567406, "title": "Ethical and legislative advances in xenotransplantation for clinical translation: focusing on cardiac, kidney and islet cell xenotransplantation", "year": 2024, "venue": "Frontiers in Immunology", "authors": [{"name": "Wayne J. Hawthorne", "authorId": "2261459618"}], "n_citations": 14}, "snippets": ["One ethical concern intrinsic to xenotransplantation relates to the potential for the transmission of diseases from animals to humans, a phenomenon known as xenozoonosis. The concept of transmission although theoretical is not unfounded, as various pathogens, including retroviruses, have been identified in pigs could be potential threats in immunocompromised transplant recipients and then theoretically spread to direct close contacts and the broader community (24,(Groenendaal et al., 2023)", "The duty to protect the broader community and prevent the spread of theoretically potential infectious diseases must be weighed against the need to explore novel medical solutions to help these patients suffering from end stage organ failure and other diseases (Hawthorne et al., 2022)", "From a patient and community perspective it is therefore essential for the patients, their family and immediate direct contacts along with the community to understand that if there were in fact a positive case of transmission of a xenozoonosis into a xenotransplant patient that there may well be serious implications to all involved. These implications are potentially as severe as lifelong restriction and quarantine of the recipient and may extend to their direct close contacts (25).\n\nXenotransplantation challenges the traditional conceptual boundaries that separate humans from animals. It poses profound philosophical and ethical questions about the nature of different species and the moral obligation we owe to different species. As we engage in practices that involve genetic modification and the use of animals for human benefit, the ethical boundaries are changing with increasing pressure on ethics committees and legislators to keep track with the pace of change, and we have a moral imperative to ensure that we do keep pace and provide adequate oversight (6).\n\nSome ethicists argue that xenotransplantation exemplifies the Anthropocentric approach (38), emphasizing human interests over those of animals, while others advocate for a more inclusive biocentric perspective that values all forms of life equally (39). The challenge is to find a balance between medical innovation and ethical responsibility to both animal and man (6)."], "score": 0.99462890625}, {"id": "(Bayliss, 2022)", "paper": {"corpus_id": 248635370, "title": "Practical ethical concerns in allocation of pig kidneys to humans", "year": 2022, "venue": "Clinical Kidney Journal", "authors": [{"name": "G. Bayliss", "authorId": "3035167"}], "n_citations": 7}, "snippets": ["Initial concerns centered on whether animal-to-human transplants violate the laws of nature and whether it is wrong to sacrifice animals as organ donors to humans. Some feared social injustice by lopsided distribution of scarce resources to a few at the expense of broader basic medical care for all. Critics wondered whether xenotransplantation would endanger public health (Vanderpool, 1998). Other pressing questions touched on prerequisites for clinical trials: identifying acceptable risk-benefit thresholds and clinically defining success (extra days versus extra weeks or months of life, for example). Some questioned whether informed consent should be obtained from close contacts of the patient and medical personnel involved in the recipient's care, given concerns about zoonotic infection. It was argued that informed consent from recipients should include a broader set of risks including public attention, risk of transmitting disease and isolation. A final set of questions touched on who is responsible for oversight of clinical trials in xenotransplantation (local hospital review boards, national committees, or some combination)?"], "score": 0.96044921875}, {"id": "(Silverman et al., 2022)", "paper": {"corpus_id": 252874917, "title": "Reevaluating the Ethical Issues in Porcine\u2010to\u2010Human Heart Xenotransplantation", "year": 2022, "venue": "The Hastings center report", "authors": [{"name": "H. Silverman", "authorId": "2034185"}, {"name": "P. Odonkor", "authorId": "5395088"}], "n_citations": 19}, "snippets": ["The ethical issues with participation in high-risk research involving xenotransplantation are unique and require careful deliberation among the transplant investigators, psychosocial providers, psychiatrists, and ethicists. To facilitate that deliberation and ensure that the wide range of ethical issues are given due consideration, we have proposed a framework that incorporates both substantive and procedural ethical values and can be used to address pa-tient selection criteria for xenotransplant clinical trials.\n\nThe assessment of benefits and risks should ensure that a trial has significant social benefit to justify excess risks that are not justified by a compensatory potential benefit to patients. The transplant team should have a heightened sensitivity to the distributive and procedural justice concerns of psychosocial criteria used in transplant listing decisions. Efforts should be made to enhance the social support available to a patient, rather than using psychosocial criteria solely to determine the listing of potential candidates. Procuring informed and voluntary consent should represent a deliberative process that occurs over several days, with participation by a representative of the hospital's clinical ethics committee."], "score": 0.978515625}, {"id": "(Cross-Najafi et al., 2022)", "paper": {"corpus_id": 247027354, "title": "Current Barriers to Clinical Liver Xenotransplantation", "year": 2022, "venue": "Frontiers in Immunology", "authors": [{"name": "Arthur A. Cross-Najafi", "authorId": "1581512634"}, {"name": "Kevin J. Lopez", "authorId": "2114919731"}, {"name": "A. Isidan", "authorId": "1390068004"}, {"name": "Yujin Park", "authorId": "74275343"}, {"name": "Wenjun Zhang", "authorId": "2124474327"}, {"name": "Ping Li", "authorId": "144785152"}, {"name": "S. Y\u0131lmaz", "authorId": "145597871"}, {"name": "S. Akbulut", "authorId": "144270397"}, {"name": "B. Ekser", "authorId": "5420001"}], "n_citations": 19}, "snippets": ["There are many ethical considerations and regulatory aspects in xenotransplantation, particularly with respect to patient consent and autonomy. These issues were previously discussed in detail (Schuurman et al., 2020)(Hurst et al., 2021). Briefly, in patients with chronic liver failure who retain capacity to make their own medical decisions the issue of patient consent is straightforward. For patients who arrive to the hospital unconscious in fulminant hepatic failure, the current standard is to place them on the waiting list for an emergent human liver allotransplant. The current ethical framework for treating life-threatening emergencies differs substantially from non-emergency situations, in that informed consent is not required in order to treat. In a scenario where the pig liver xenotransplantation is a reasonable alternative, the clinician would be required to choose between placing the patient on the waiting list or proceeding with liver xenotransplantation with an informed consent obtained from the family and/or hospital's ethical committee."], "score": 0.9599609375}, {"id": "(Schuurman et al., 2020)", "paper": {"corpus_id": 219330997, "title": "Solid organ xenotransplantation at the interface between research and clinical development: Regulatory aspects", "year": 2020, "venue": "Xenotransplantation", "authors": [{"name": "H. Schuurman", "authorId": "143715061"}, {"name": "K. Hoogendoorn", "authorId": "145679624"}], "n_citations": 14}, "snippets": ["During the last years, progress has been made in survival and function of pig\u2010to\u2010non\u2010human primate organ xenotransplantation using organs from genetically modified pigs and immunosuppression regimens that are clinically acceptable. This, together with increased insights into a low risk of pig\u2010to\u2010human transmission of porcine endogenous retrovirus, has opened the perspective of starting with first\u2010in\u2010human trials with xenogeneic organs. The regulatory path to clinical development is complex. Unlike an organ from human donors, an organ from pigs, either genetically modified or wild\u2010type pigs, is considered a medicinal product for human use and hence is under regulatory oversight, in the United States by the Food and Drug Administration and in Europe by the national competent authorities of the member states as well as the European Medicines Agency. Related to the status of medicinal product, \"(current) good practices\" apply in the process of generating a xenogeneic organ through to the transplantation into a patient and life\u2010long follow\u2010up. In addition, guidances for xenotransplantation products and genetically modified organisms do apply as well. This commentary focuses on regulatory aspects of transplantation of organs from genetically modified pigs into humans, with the intention to facilitate the interactions between regulatory agencies and institutions (sponsors) in research and clinical development of these organs, to support the perspective of speeding up the process with a proper entry in clinical application, to fill an unmet medical need in patients with end\u2010stage organ disease."], "score": 0.0}, {"id": "(Hurst et al., 2021)", "paper": {"corpus_id": 244428525, "title": "Scientific and psychosocial ethical considerations for initial clinical trials of kidney xenotransplantation", "year": 2021, "venue": "Xenotransplantation", "authors": [{"name": "Daniel J. Hurst", "authorId": "34438297"}, {"name": "Luz A. Padilla", "authorId": "39854888"}, {"name": "D. Cooper", "authorId": "1992982"}, {"name": "W. Paris", "authorId": "3209193"}], "n_citations": 15}, "snippets": ["The initial clinical trials of pig solid organ xenotransplantation (XTx) are drawing closer and could begin in the coming years. The first clinical trials may aim to transplant genetically\u2010modified pig kidneys into adult humans. The impetus for beginning these first\u2010in\u2010human trials is the severe lack of deceased donor kidneys for transplantation and the number of patients with end\u2010stage renal disease currently on transplant waitlists, which in the USA approaches 100 000. The majority of patients on the kidney transplant waitlist receive continuous renal replacement therapy. In the United States, for patients on the kidney waitlist, the median wait\u2010time to receive a deceased human donor organ is approximately 4.5 years for patients aged 45\u201374, with a 5\u2010year mortality (or removal from the waitlist because of deteriorating health) of approximately 40%. XTx has the potential to reduce the kidney waitlist morbidity and mortality while improving quality of life. By focusing on scientific and psychosocial criteria, we present ethical considerations of certain inclusion and exclusion criteria for these first\u2010in\u2010human clinical trials that we suggest have not yet been fully explored."], "score": 0.0}, {"id": "(Gordon et al., 2025)", "paper": {"corpus_id": 276578858, "title": "Patients\u2019 Information Needs for Informed Consent to Participate in First\u2010in\u2010Human Pig Kidney Xenotransplant Clinical Trials: A Mixed Methods Study", "year": 2025, "venue": "Xenotransplantation", "authors": [{"name": "Elisa J. Gordon", "authorId": "2185546879"}, {"name": "Mickael K. Gusmano", "authorId": "2258689847"}, {"name": "Jessica Gacki-Smith", "authorId": "1399002102"}, {"name": "Hannah L Brooks", "authorId": "2344060875"}, {"name": "Margaret M Matthews", "authorId": "2344072682"}, {"name": "Dahlya Manning", "authorId": "2344068356"}, {"name": "Joseph Leventhal", "authorId": "2344060667"}, {"name": "K. Maschke", "authorId": "4295444"}], "n_citations": 0}, "snippets": ["The unknown potential to transmit known and unknown diseases from the pig organ to human recipient [16,17] elevates the risk profile of first-in-human pig kidney xenotransplant trials.\n\nMagnifying these challenges is that few, if any, treatment alternatives for patients with end-stage kidney disease exist, which can render patients vulnerable and undermine voluntary decision-making [12,13]. Such vulnerability commonly occurs among patients undergoing innovative surgical procedures for which alternative standard treatments are either ineffective or nonexistent [21].\n\nThe ethical challenges to informed consent comprise a component of translational research that requires resolution. Current federal regulations (i.e., the National Organ Transplant Act of 1984) lack guidance on informed consent for xenotransplant clinical trials [22]. Organ Procurement and Transplant Network policies only pertain to human organs. Thus, policies on information disclosure may not translate to the xenotransplant context."], "score": 0.96435546875}, {"id": "(Shirini et al., 2025)", "paper": {"corpus_id": 276610974, "title": "Xenotransplantation Literature Update July\u2013December 2024", "year": 2025, "venue": "Xenotransplantation", "authors": [{"name": "Kasra Shirini", "authorId": "2340672108"}, {"name": "J. Ladowski", "authorId": "2261605136"}, {"name": "Raphael P. H. Meier", "authorId": "2261558306"}], "n_citations": 1}, "snippets": ["The ethical framework of xenotransplantation continues to evolve in response to societal reactions and public discourse surrounding early cases of xenotransplantation. These discussions highlighted tensions between scientific progress and societal ethical standards, underscoring the need for proactive public engagement to build trust and address normative judgments that influence societal acceptance and regulatory approaches to emerging biotechnologies [15]. The progression toward clinical xenotransplantation trials necessitates a patient selection process grounded in medical need, capacity to benefit, patient choice, and compliance to achieve ethically sound and scientifically valuable outcomes [16,17].\n\nOne of the most pressing ethical dilemmas in xenotransplantation is the selection of patients for clinical trials. Current recommendations prioritize critically ill patients who have exhausted all other therapeutic options. However, this approach has been criticized for its potential to produce unfavorable risk-benefit ratios, particularly for patients with complex medical conditions. Furthermore, concerns about justice and beneficence arise when considering acutely ill patients who may struggle to provide fully informed consent [19].\n\nIssues such as informed consent-particularly for minors-and the psychosocial impacts on patients and their families further complicate the discourse. Public perception adds another layer of difficulty, especially when determining whether adults or children should be prioritized in early clinical trials."], "score": 0.99560546875}, {"id": "(Groth, 2007)", "paper": {"corpus_id": 29444854, "title": "The potential advantages of transplanting organs from pig to man: A transplant Surgeon's view", "year": 2007, "venue": "Indian Journal of Urology", "authors": [{"name": "C. Groth", "authorId": "89217942"}], "n_citations": 17}, "snippets": ["There are several ethical issues pertaining to clinical xenotransplantation. One such issue concerns defining the harm/benefit ratio in the context of the initial clinical attempts. It might also be difficult to institute an appropriate informed-consent procedure. The fact that the patients will have to be monitored for possible infectious diseases for an extended time, possibly for life, is another ethical concern.\n\nMoreover, there are a number of ethical issues with regards to society at large. The public health hazard posed by the possible transmission and activation of PERV created considerable public concern a few years ago. The public debate that took place also generated some emotionally colored skepticism towards xenotransplantation, in which it was argued that \"transplantation from animal to man will violate the order of nature\". Other objections were with regard to the safety of the future recipients: \"xenotransplantation will constitute experimentation on sick human beings\"."], "score": 0.95947265625}], "table": null}, {"title": "Broader Societal and Philosophical Considerations", "tldr": "Xenotransplantation challenges fundamental philosophical boundaries between humans and animals, raising questions about human identity, interference with nature, and distributive justice in healthcare resource allocation. These considerations extend beyond clinical concerns to include cultural, religious, and psychological dimensions that require broad societal engagement and democratic debate. (14 sources)", "text": "\nXenotransplantation raises profound philosophical questions about the boundaries that separate humans from animals and our ethical obligations to different species. This medical innovation forces society to confront what it means anthropologically for humans to live with animal organs or tissues <Paper corpusId=\"221108043\" paperTitle=\"(Kogel et al., 2020)\" isShortName></Paper>. The integration of animal organs into human bodies potentially challenges personal identity and may create psychological and physiological issues for recipients <Paper corpusId=\"71697624\" paperTitle=\"(Yaakob et al., 2011)\" isShortName></Paper>. These concerns are particularly acute when human-pig chimeras containing human genes and cells are used, as they represent what some view as a \"deep transgression of the natural order\" for theological, ecological, or dignity-related reasons <Paper corpusId=\"58644768\" paperTitle=\"(Casal et al., 2019)\" isShortName></Paper>.\n\nThe ethical framework used to evaluate xenotransplantation is itself contested. Many analyses follow an anthropocentric approach that prioritizes human interests over those of animals, while others advocate for a more inclusive biocentric perspective that values all forms of life equally <Paper corpusId=\"253286042\" paperTitle=\"(Oli et al., 2022)\" isShortName></Paper> <Paper corpusId=\"221306753\" paperTitle=\"(Cengiz et al., 2020)\" isShortName></Paper>. This tension reflects fundamental disagreements about whether humans have the right to use animals as \"organic spare parts\" <Paper corpusId=\"221108043\" paperTitle=\"(Kogel et al., 2020)\" isShortName></Paper> and whether such practices constitute impermissible \"interference with nature\" <Paper corpusId=\"253286042\" paperTitle=\"(Oli et al., 2022)\" isShortName></Paper>.\n\nResource allocation and distributive justice represent another significant ethical dimension. Questions have been raised about whether the substantial resources required for xenotransplantation represent a fair distribution, particularly when many lack access to basic healthcare <Paper corpusId=\"248635370\" paperTitle=\"(Bayliss, 2022)\" isShortName></Paper>. These concerns are complicated by the existing confusion among patients regarding organ allocation systems, which xenotransplantation would further complicate <Paper corpusId=\"249734546\" paperTitle=\"(Boulet et al., 2022)\" isShortName></Paper>.\n\nThe psychological and social adaptation of xenotransplant recipients merits special consideration but has received less attention than technological development <Paper corpusId=\"269698591\" paperTitle=\"(Zhang et al., 2024)\" isShortName></Paper>. Pediatric xenotransplantation raises additional concerns about psychological burdens and organ sizing issues <Paper corpusId=\"273237447\" paperTitle=\"(Merlocco et al., 2024)\" isShortName></Paper>. As the field advances, addressing these psychological dimensions will be essential for comprehensive patient care.\n\nThe introduction of human DNA into animals at early developmental stages raises specific concerns about human cells potentially populating animal brains or germlines. The first scenario might confer morally relevant human traits to animals, while the second could lead to transmission of human genes if animals were accidentally released <Paper corpusId=\"58644768\" paperTitle=\"(Casal et al., 2019)\" isShortName></Paper>. These possibilities have prompted regulatory caution, including temporary suspension of funding by the US National Institutes of Health for chimeric xenotransplantation research.\n\nReligious and cultural perspectives add another layer of complexity. Concerns may arise particularly when certain animals, such as pigs, are used as organ sources in communities where these animals have specific cultural or religious significance <Paper corpusId=\"71697624\" paperTitle=\"(Yaakob et al., 2011)\" isShortName></Paper>. Addressing these cultural dimensions requires inclusive dialogue that respects diverse perspectives.\n\nUnlike many medical innovations, xenotransplantation raises ethical issues that have not been formally discussed or agreed upon in the public arena <Paper corpusId=\"28577007\" paperTitle=\"(Sim et al., 1999)\" isShortName></Paper>. The medical and scientific communities have a responsibility to provide sufficient information to enable informed public debate <Paper corpusId=\"28577007\" paperTitle=\"(Sim et al., 1999)\" isShortName></Paper>. This debate must balance the duty to protect broader community health against the need to explore novel medical solutions for patients with end-stage organ failure <Paper corpusId=\"267567406\" paperTitle=\"(Hawthorne, 2024)\" isShortName></Paper>.\n\nAs advances in xenotransplantation continue, these broader societal and philosophical considerations require comprehensive ethical assessment involving all stakeholders, including the general public <Paper corpusId=\"267158980\" paperTitle=\"(Coelho, 2023)\" isShortName></Paper> <Paper corpusId=\"51611995\" paperTitle=\"(Loike et al., 2018)\" isShortName></Paper>. Finding an ethical balance between medical innovation and responsibility to both animals and humans remains a crucial challenge as the field moves toward clinical application <Paper corpusId=\"267567406\" paperTitle=\"(Hawthorne, 2024)\" isShortName></Paper> <Paper corpusId=\"262207976\" paperTitle=\"(Kwisda, 2023)\" isShortName></Paper>.", "citations": [{"id": "(Kogel et al., 2020)", "paper": {"corpus_id": 221108043, "title": "\u201cXenotransplantation challenges us as a society\u201d", "year": 2020, "venue": "EMBO Reports", "authors": [{"name": "Johannes K\u00f6gel", "authorId": "144208416"}, {"name": "G. Marckmann", "authorId": "2065192923"}], "n_citations": 19}, "snippets": ["While these advances in XT provide hope for patients with irreversible organ failure, they also raise ethical and philosophical issues: Is it ethically acceptable to breed animals and use them as an organic spare parts stock? What does it mean anthropologically for patients to live with an animal organ or animal tissue? How shall we balance the potential benefits and risks of XT therapies, given that everyone could potentially benefit as an organ recipient, but at the same time may risk acquiring a xenogeneic infectious disease?"], "score": 0.962890625}, {"id": "(Yaakob et al., 2011)", "paper": {"corpus_id": 71697624, "title": "The Legal and Ethical Dilemmas in Keeping Abreast with Innovations in Medical Sciences", "year": 2011, "venue": "", "authors": [{"name": "Haniwarda Yaakob", "authorId": "80399170"}, {"name": "Z. Yaakob", "authorId": "35218052"}, {"name": "Nooraain Hashim", "authorId": "34770635"}], "n_citations": 1}, "snippets": ["Xenotransplantation involves \"", "the transplantation of tissue and organs between different species, and in particular the transplantation of animal tissue into humans.\" (http://www.dh.gov/ab/Archive/UKXIRA/DH_087869). The technology is being developed with the hope of providing a solution to the shortage of human organs for transplantation. However, several concerns have been put forward on the ethics, morality and safety of the technique. For example, it has been suggested that organs transplantation may raise \"emotional, personal identity issues\" for some people and this \"feeling\" might be heightened when non-human organs are transplanted into human beings (Sykes et al., 2003). Having animal organs or tissue in a human body is likely to raise \"physiological and psychological issues.\" (Hagelin, 2004). More importantly, the ethics of rearing animals with the sole purpose of harvesting their organs for transplantation needs to be examined (Sykes et al., 2003). This issue must be further ascertained from the Islamic perspective particularly when pigs are involved due to Islamic prohibition on the consumption of the animal.\n\nThe use of non-human organs further raises concerns on the interests of society at large. The transplantation of non-human organs into human beings exposes the recipient and society to the risks of virus transmission (Sykes et al., 2003). This may occur when the organ harvested from the animal contains an infectious virus and is transmitted to the human recipient who may then spread the virus to others (Hagelin, 2004)."], "score": 0.96240234375}, {"id": "(Casal et al., 2019)", "paper": {"corpus_id": 58644768, "title": "Human iPSC-Chimera Xenotransplantation and the Non-Identity Problem", "year": 2019, "venue": "Journal of Clinical Medicine", "authors": [{"name": "P. Casal", "authorId": "115920900"}, {"name": "Andrew J. Williams", "authorId": "1748359546"}], "n_citations": 5}, "snippets": ["In cases of xenotransplantation, when the donor and the recipient belong to different species, further issues arise, regarding (i) the unavoidable harms to the donor and (ii) the possible harms to the recipients. When the donor is a chimeric pig, designed to contain a percentage of human genes and cells, xenotransplantation provokes two opposing sets of reactions [5].\n\nFor some, the use of human-pig chimeras strengthens both recipient-based and donor-based objections, rendering xenotransplantation more objectionable or even impermissible. Many feel an aversion to such a deep transgression of the natural order, for reasons that may be theological, ecological, or involve human dignity, animal rights or fear of scientists yet again producing undesirable, unforeseen, and irreversible consequences. Others have more specific concerns. For example, the US National Institutes of Health suspended funding of their chimeric xenotransplantation program in 2015 over concerns about introducing human DNA into a member of another species, and particularly doing so at such an early developmental stage. As Carrie Wolinetz, Salz Institute's Associate Director for Science Policy, explains: 'people were concerned about human cells populating the brain of the animal or the germline of the animal' [6]. In the first case, the animal might acquire morally relevant human traits; in the second case, the animal might transmit human genes and traits to its offspring, for example, if accidentally released into the wild."], "score": 0.97314453125}, {"id": "(Oli et al., 2022)", "paper": {"corpus_id": 253286042, "title": "Classic and Current Opinions in Human Organ and Tissue Transplantation", "year": 2022, "venue": "Cureus", "authors": [{"name": "A. Oli", "authorId": "6234364"}, {"name": "Adekunle Babajide Rowaiye", "authorId": "2148618005"}, {"name": "S. Adejumo", "authorId": "2189658445"}, {"name": "F. I. Anazodo", "authorId": "2189658242"}, {"name": "Rahnuma Ahmad", "authorId": "2054233390"}, {"name": "Susmita Sinha", "authorId": "46534705"}, {"name": "Mainul Haque", "authorId": "2061252439"}, {"name": "Nihad Adnan", "authorId": "6323392"}], "n_citations": 7}, "snippets": ["Another fundamental challenge facing xenograft is ethical issues. Three ethical issues quickly come to mind when we talk of xenotransplantation: animal rights (effects on the donor animal), human rights (the impact on the human population and the impact on the individual recipient), and interference with nature. An animal rights issue arises because animals, like humans, also have rights to existence and should not be sacrificed in favor of humans (Cengiz et al., 2020). Human rights regarding the recipient can quickly be cleared by obtaining the necessary informed consent. Still, the populace also needs authorization because of the possibility of transferring new pathogens from animal to human populations -a public health risk (Abouna, 2003). The ethical issue of interference with nature may not be so applied. It may be understandable that by interfering with nature, man can free himself from the extinction effects of some natural phenomena [28]."], "score": 0.98046875}, {"id": "(Cengiz et al., 2020)", "paper": {"corpus_id": 221306753, "title": "Ethical considerations in xenotransplantation: a review", "year": 2020, "venue": "Current Opinion in Organ Transplantation", "authors": [{"name": "N. Cengiz", "authorId": "1907504545"}, {"name": "C. Wareham", "authorId": "145619065"}], "n_citations": 15}, "snippets": ["Purpose of review The purpose of this review is to present and analyse recent literature on the patterns, trends, and developments of ethical considerations concerning xenotransplantation by appraising normative aspects within a coherent framework. Recent findings Developments within xenotransplantation may soon allow for pig-to-human xenotransplantation to take place. Ethical analysis of xenotransplantation commonly follows an anthropocentric cost\u2013benefit analysis, which may imprecisely measure costs. Xenotransplantation should not merely be approached from an anthropocentric perspective. Rather, the potential risks presented to human and nonhuman donors, recipients, and third parties should all be thoroughly considered. Summary The range of feasible alternatives to xenotransplantation to increase organ supply should be examined before resorting to xenotransplantation because of the moral distinction between imposing certain risks on others before, or after, alternative solutions have been exhausted."], "score": 0.0}, {"id": "(Bayliss, 2022)", "paper": {"corpus_id": 248635370, "title": "Practical ethical concerns in allocation of pig kidneys to humans", "year": 2022, "venue": "Clinical Kidney Journal", "authors": [{"name": "G. Bayliss", "authorId": "3035167"}], "n_citations": 7}, "snippets": ["Initial concerns centered on whether animal-to-human transplants violate the laws of nature and whether it is wrong to sacrifice animals as organ donors to humans. Some feared social injustice by lopsided distribution of scarce resources to a few at the expense of broader basic medical care for all. Critics wondered whether xenotransplantation would endanger public health (Vanderpool, 1998). Other pressing questions touched on prerequisites for clinical trials: identifying acceptable risk-benefit thresholds and clinically defining success (extra days versus extra weeks or months of life, for example). Some questioned whether informed consent should be obtained from close contacts of the patient and medical personnel involved in the recipient's care, given concerns about zoonotic infection. It was argued that informed consent from recipients should include a broader set of risks including public attention, risk of transmitting disease and isolation. A final set of questions touched on who is responsible for oversight of clinical trials in xenotransplantation (local hospital review boards, national committees, or some combination)?"], "score": 0.96044921875}, {"id": "(Boulet et al., 2022)", "paper": {"corpus_id": 249734546, "title": "Cardiac Xenotransplantation", "year": 2022, "venue": "JACC: Basic to Translational Science", "authors": [{"name": "J. Boulet", "authorId": "147033575"}, {"name": "J. Cunningham", "authorId": "12848802"}, {"name": "M. Mehra", "authorId": "1810556"}], "n_citations": 12}, "snippets": ["One major ethical consideration in XTx is the concern for animal rights and the anthropocentric view of putting humans above all other animal species. (Cengiz et al., 2020) The welfare of animals being bred in laboratories with living conditions that significantly differ from their usual environments will need to be defined. (1998) Other challenges include the fairness of resource allocation and distributive justice, in an era when there is already much confusion in patients with respect to the current organ allocation system.\n\nAnother major aspect will be appropriately educating clinicians and patients, particularly with respect to the challenge of obtaining well-informed consent in an area with a high degree of uncertainty. These considerable ethical, social, and legal challenges will require careful consideration and discourse in a manner concurrent with scientific advances in the field."], "score": 0.97607421875}, {"id": "(Zhang et al., 2024)", "paper": {"corpus_id": 269698591, "title": "The Dilemma of Ethical Recipients of Xenotransplantation under the Biopsychosocialmedical Model", "year": 2024, "venue": "MEDS Public Health and Preventive Medicine", "authors": [{"name": "Xinwen Zhang", "authorId": "2300985036"}, {"name": "Gang Li", "authorId": "2301089230"}], "n_citations": 0}, "snippets": ["In recent years, there have been continuous reports of new breakthroughs in clinical xenotransplantation, indicating that xenotransplantation is expected to become the main method of clinical transplantation. However, at present, clinical workers mostly focus on technological development and current clinical trial ethical principles, to some extent neglecting the psychological and social adaptability of individuals."], "score": 0.9482421875}, {"id": "(Merlocco et al., 2024)", "paper": {"corpus_id": 273237447, "title": "Challenges in Paediatric Xenotransplantation: Ethical Components Requiring Distinct Attention in Children and Obligations to Patients and Society.", "year": 2024, "venue": "Journal of Bioethical Inquiry", "authors": [{"name": "Anthony Merlocco", "authorId": "12294049"}, {"name": "D. Hurst", "authorId": "2261600572"}], "n_citations": 1}, "snippets": ["In this paper, we explore ethical challenges to be expected in paediatric XTx, in particular exploring organ sizing concerns, infectious risks, psychological burdens, and issues of moral hazard."], "score": 0.9912109375}, {"id": "(Sim et al., 1999)", "paper": {"corpus_id": 28577007, "title": "Xenotransplantation: A potential solution to the critical organ donor shortage.", "year": 1999, "venue": "Canadian journal of gastroenterology = Journal canadien de gastroenterologie", "authors": [{"name": "K Howe Sim", "authorId": "2271839474"}, {"name": "Anton Marinov", "authorId": "2272149804"}, {"name": "Gary A Levy", "authorId": "2271801166"}], "n_citations": 24}, "snippets": ["Unlike other areas of clinical medicine, xenotransplantation raises a variety of ethical issues that have not been formally discussed or agreed upon in the public arena.The general public must play a role in defining ethical policies regarding xenotransplantation, and it is the duty of the medical and scientific communities to provide as much information as possible to them, so that public policies can be formulated in an informed manner.\n\nThe clinical application of xenotransplantation is predicated on the assumption that the use of animals in medical research and therapy is morally acceptable.Even if this debatable principle is accepted, the use of animals in xenotransplantation, particularly nonhuman primates, raises additional issues.That these animals may need to be genetically altered to overcome certain immunological obstacles further complicates their use as experimental subjects."], "score": 0.97900390625}, {"id": "(Hawthorne, 2024)", "paper": {"corpus_id": 267567406, "title": "Ethical and legislative advances in xenotransplantation for clinical translation: focusing on cardiac, kidney and islet cell xenotransplantation", "year": 2024, "venue": "Frontiers in Immunology", "authors": [{"name": "Wayne J. Hawthorne", "authorId": "2261459618"}], "n_citations": 14}, "snippets": ["One ethical concern intrinsic to xenotransplantation relates to the potential for the transmission of diseases from animals to humans, a phenomenon known as xenozoonosis. The concept of transmission although theoretical is not unfounded, as various pathogens, including retroviruses, have been identified in pigs could be potential threats in immunocompromised transplant recipients and then theoretically spread to direct close contacts and the broader community (24,(Groenendaal et al., 2023)", "The duty to protect the broader community and prevent the spread of theoretically potential infectious diseases must be weighed against the need to explore novel medical solutions to help these patients suffering from end stage organ failure and other diseases (Hawthorne et al., 2022)", "From a patient and community perspective it is therefore essential for the patients, their family and immediate direct contacts along with the community to understand that if there were in fact a positive case of transmission of a xenozoonosis into a xenotransplant patient that there may well be serious implications to all involved. These implications are potentially as severe as lifelong restriction and quarantine of the recipient and may extend to their direct close contacts (25).\n\nXenotransplantation challenges the traditional conceptual boundaries that separate humans from animals. It poses profound philosophical and ethical questions about the nature of different species and the moral obligation we owe to different species. As we engage in practices that involve genetic modification and the use of animals for human benefit, the ethical boundaries are changing with increasing pressure on ethics committees and legislators to keep track with the pace of change, and we have a moral imperative to ensure that we do keep pace and provide adequate oversight (6).\n\nSome ethicists argue that xenotransplantation exemplifies the Anthropocentric approach (38), emphasizing human interests over those of animals, while others advocate for a more inclusive biocentric perspective that values all forms of life equally (39). The challenge is to find a balance between medical innovation and ethical responsibility to both animal and man (6)."], "score": 0.99462890625}, {"id": "(Coelho, 2023)", "paper": {"corpus_id": 267158980, "title": "Xenotransplanta\u00e7\u00e3o: pr\u00f3s e contras", "year": 2023, "venue": "Problemata", "authors": [{"name": "Gustavo Henrique de Freitas Coelho", "authorId": "2280718706"}], "n_citations": 0}, "snippets": ["it raises several issues that must be widely analyzed and democratically debated by society, such as: the risk of xenozoonosis, the use of non-human animals, the limitation of the privacy of recipients of organs of animal origin, collection protocols of free and informed consent and the use of brain-dead patients in experiments."], "score": 0.9697265625}, {"id": "(Loike et al., 2018)", "paper": {"corpus_id": 51611995, "title": "Ethical rejections of xenotransplantation?", "year": 2018, "venue": "EMBO Reports", "authors": [{"name": "J. Loike", "authorId": "6640459"}, {"name": "A. Kadish", "authorId": "33343304"}], "n_citations": 20}, "snippets": ["While the medical benefits of xenotransplantation appear to be significant, we discuss specific ethical, medical, cultural, and financial challenges and potential solutions that need to be addressed before clinical trials using organs from human\u2010animal chimeras should begin."], "score": 0.958984375}, {"id": "(Kwisda, 2023)", "paper": {"corpus_id": 262207976, "title": "Unaddressed regulatory issues in xenotransplantation: a hypothetical example", "year": 2023, "venue": "Frontiers in Transplantation", "authors": [{"name": "Koko Kwisda", "authorId": "122102224"}], "n_citations": 1}, "snippets": ["In addition, there are numerous ethical issues pertaining to xenotransplantation, which have been discussed for years (28)(29)(30)(31)(32)(33) and fall into three broad categories: the first argues that certain scientific experiments should simply not be undertaken; the second warns of unforeseen consequences of genetically altering organisms; and the third pertains to the suffering of involved animals. In addition, there is a continuous and heated debate about the permissibility of mixing animal and human material in the academic (34-36) as well as the public sector (37)(38)(39)."], "score": 0.97412109375}], "table": null}, {"title": "Regulatory and Governance Frameworks", "tldr": "Xenotransplantation requires comprehensive regulatory frameworks that address safety, ethical oversight, and cross-border coordination. Current governance structures are evolving but remain incomplete, necessitating specialized ethics committees, patient monitoring protocols, and international standards to manage both individual and public health risks. (12 sources)", "text": "\nThe regulatory landscape for xenotransplantation remains underdeveloped despite significant scientific advances in the field. A fundamental challenge is the absence of specific legislation governing xenotransplantation, which necessitates evolution of regulatory frameworks to enhance research protocols and future clinical applications <Paper corpusId=\"268641927\" paperTitle=\"(Zhang et al._1, 2024)\" isShortName></Paper>. This regulatory gap is particularly concerning given that oversight responsibilities for xenotransplantation clinical trials remain unclear, with questions about whether local hospital review boards, national committees, or some combination should have authority <Paper corpusId=\"248635370\" paperTitle=\"(Bayliss, 2022)\" isShortName></Paper>.\n\nExperts emphasize that before any clinical trials are approved, a legally binding regulatory framework and mechanism should be established to control the safety and quality of animal organs <Paper corpusId=\"252891241\" paperTitle=\"(Zhai, 2022)\" isShortName></Paper>. These frameworks must address the unique nature of xenotransplantation as a medical technology that poses risks not only to individual patients but potentially to public health more broadly <Paper corpusId=\"34061863\" paperTitle=\"(Kaiser, 2004)\" isShortName></Paper>. Unlike conventional medical technologies that typically require assessment when ready for clinical use, xenotransplantation demands proactive regulatory action at a very early stage of development <Paper corpusId=\"34061863\" paperTitle=\"(Kaiser, 2004)\" isShortName></Paper>.\n\nInternational coordination represents another critical regulatory challenge. The cross-border implications of xenotransplantation necessitate agreements to cover scenarios where recipients might receive initial treatment in one jurisdiction but move to another <Paper corpusId=\"265121285\" paperTitle=\"(Thom et al., 2023)\" isShortName></Paper>. Experts have called for international guidelines, compatible information technology, and standardized reporting norms to prevent the transfer of pathogens from source animals to humans <Paper corpusId=\"260047382\" paperTitle=\"(Ku, 2004)\" isShortName></Paper>. Questions remain about who should bear the costs for these international initiatives and public health safety mechanisms <Paper corpusId=\"260047382\" paperTitle=\"(Ku, 2004)\" isShortName></Paper>.\n\nThe composition of regulatory bodies is also critical. Ethics review committees should include specialized and competent scientific, medical, ethical, and related disciplinary experts capable of conducting in-depth analysis of the ethical, social, and philosophical issues arising from xenotransplantation <Paper corpusId=\"252891241\" paperTitle=\"(Zhai, 2022)\" isShortName></Paper>. This multidisciplinary approach is essential for addressing the complex ethical considerations that continue to evolve in response to societal reactions and public discourse surrounding early xenotransplantation cases <Paper corpusId=\"276610974\" paperTitle=\"(Shirini et al., 2025)\" isShortName></Paper>.\n\nRecent pilot xenotransplantation trials have highlighted various medicolegal considerations, including adherence to established guidelines such as the Uniform Anatomical Gift Act and the dead-donor rule <Paper corpusId=\"268641927\" paperTitle=\"(Zhang et al._1, 2024)\" isShortName></Paper> <Paper corpusId=\"246137465\" paperTitle=\"(Porrett et al., 2022)\" isShortName></Paper> <Paper corpusId=\"248860025\" paperTitle=\"(Montgomery et al., 2022)\" isShortName></Paper>. The FDA's 2022 approval of a pig-to-human heart transplant under an \"Expanded Access\" application represents a significant regulatory milestone, though many challenges remain <Paper corpusId=\"268641927\" paperTitle=\"(Zhang et al._1, 2024)\" isShortName></Paper> <Paper corpusId=\"252382225\" paperTitle=\"(Singh et al., 2022)\" isShortName></Paper>.\n\nInformed consent processes within regulatory frameworks for xenotransplantation trials require special consideration. Some experts recommend that consent should represent a deliberative process occurring over several days, with participation by representatives from clinical ethics committees <Paper corpusId=\"252874917\" paperTitle=\"(Silverman et al., 2022)\" isShortName></Paper>. Questions persist about whether informed consent should be obtained not only from recipients but also from close contacts and medical personnel, given concerns about zoonotic infection <Paper corpusId=\"248635370\" paperTitle=\"(Bayliss, 2022)\" isShortName></Paper>.\n\nPatient selection criteria for clinical trials present another regulatory challenge. Current recommendations often prioritize critically ill patients who have exhausted other therapeutic options, but this approach has been criticized for potentially unfavorable risk-benefit ratios <Paper corpusId=\"276610974\" paperTitle=\"(Shirini et al., 2025)\" isShortName></Paper>. Regulatory frameworks must balance ensuring significant social benefit to justify excess risks while maintaining sensitivity to distributive and procedural justice concerns <Paper corpusId=\"252874917\" paperTitle=\"(Silverman et al., 2022)\" isShortName></Paper>.\n\nThe monitoring requirements imposed on xenotransplantation recipients, their close contacts, and clinical personnel represent a significant regulatory burden that must be carefully structured to protect both individual and public health <Paper corpusId=\"265121285\" paperTitle=\"(Thom et al., 2023)\" isShortName></Paper>. These monitoring protocols constitute an essential component of risk assessment, risk management, and risk prevention as public health tools <Paper corpusId=\"260047382\" paperTitle=\"(Ku, 2004)\" isShortName></Paper>.\n\nAs the field advances toward clinical application, these regulatory and governance challenges must be addressed through continued research, dialogue, and education <Paper corpusId=\"268641927\" paperTitle=\"(Zhang et al._1, 2024)\" isShortName></Paper> <Paper corpusId=\"271513704\" paperTitle=\"(Thuan et al., 2024)\" isShortName></Paper>. The ultimate goal remains the development of regulatory frameworks that effectively balance scientific progress with ethical standards and public health protection <Paper corpusId=\"276610974\" paperTitle=\"(Shirini et al., 2025)\" isShortName></Paper>.", "citations": [{"id": "(Zhang et al._1, 2024)", "paper": {"corpus_id": 268641927, "title": "Advancing kidney xenotransplantation with anesthesia and surgery - bridging preclinical and clinical frontiers challenges and prospects", "year": 2024, "venue": "Frontiers in Immunology", "authors": [{"name": "Xiaojian Zhang", "authorId": "2108198650"}, {"name": "Hailian Wang", "authorId": "2293137477"}, {"name": "Qin Xie", "authorId": "2293027037"}, {"name": "Yang Zhang", "authorId": "2293251553"}, {"name": "Yixin Yang", "authorId": "2293037013"}, {"name": "Man Yuan", "authorId": "2293190137"}, {"name": "Yuqi Cui", "authorId": "2293131966"}, {"name": "Sicheng Song", "authorId": "2265959826"}, {"name": "Jianzhen Lv", "authorId": "4377486"}, {"name": "Yi Wang", "authorId": "2293178739"}], "n_citations": 0}, "snippets": ["Additionally, the ethical landscape of xenotransplantation, encompassing animal rights, public attitudes, and regulatory milestones such as the FDA's 2022 approval of a pig-to-human heart transplant, presents ongoing challenges (Singh et al., 2022). The pilot xenotransplantation trials have underscored various ethical and medicolegal considerations inherent in xenotransplantation research (Porrett et al., 2022)(Montgomery et al., 2022). In these studies, brain-dead decedents were precluded from organ donation, and obtaining proper informed consent from their families was deemed essential. Notably, the absence of specific legislation governing xenotransplantation necessitates evolution of the regulatory frameworks to enhance research protocols and future clinical applications. Consultation with ethics committees is imperative to ensure adherence to established guidelines such as the Uniform Anatomical Gift Act (UAGA) and the dead-donor rule, while also acknowledging the cultural and religious nuances surrounding organ transplantation (30). Public acceptance and ethical considerations remain integral to the advancement and clinical application of xenotransplantation, highlighting the need for continued research, dialogue, and education in this evolving field."], "score": 0.98486328125}, {"id": "(Bayliss, 2022)", "paper": {"corpus_id": 248635370, "title": "Practical ethical concerns in allocation of pig kidneys to humans", "year": 2022, "venue": "Clinical Kidney Journal", "authors": [{"name": "G. Bayliss", "authorId": "3035167"}], "n_citations": 7}, "snippets": ["Initial concerns centered on whether animal-to-human transplants violate the laws of nature and whether it is wrong to sacrifice animals as organ donors to humans. Some feared social injustice by lopsided distribution of scarce resources to a few at the expense of broader basic medical care for all. Critics wondered whether xenotransplantation would endanger public health (Vanderpool, 1998). Other pressing questions touched on prerequisites for clinical trials: identifying acceptable risk-benefit thresholds and clinically defining success (extra days versus extra weeks or months of life, for example). Some questioned whether informed consent should be obtained from close contacts of the patient and medical personnel involved in the recipient's care, given concerns about zoonotic infection. It was argued that informed consent from recipients should include a broader set of risks including public attention, risk of transmitting disease and isolation. A final set of questions touched on who is responsible for oversight of clinical trials in xenotransplantation (local hospital review boards, national committees, or some combination)?"], "score": 0.96044921875}, {"id": "(Zhai, 2022)", "paper": {"corpus_id": 252891241, "title": "Xenotransplantation\u2014reflections on the bioethics", "year": 2022, "venue": "Health Care Science", "authors": [{"name": "Xiaomei Zhai", "authorId": "2315299"}], "n_citations": 3}, "snippets": ["Before any clinical trials are approved or take place, a legally binding regulatory framework and regulatory mechanism should be established for the use of animal organs to control the safety and quality of animal organs The ethics review committee should be composed of specialized and competent scientific, medical, ethical and related disciplinary experts.So as to be able to conduct indepth analysis and discussion on the ethical, social, and even philosophical issues arising from xenotransplantation."], "score": 0.95703125}, {"id": "(Kaiser, 2004)", "paper": {"corpus_id": 34061863, "title": "Xenotransplantation: Ethical considerations based on human and societal perspectives", "year": 2004, "venue": "", "authors": [{"name": "M. Kaiser", "authorId": "39600443"}], "n_citations": 9}, "snippets": ["Xenotransplantation marks a qualitatively new challenge in medical technology assessment. The reasons for this claim are twofold: (i) in contrast to more traditional medical interventions, xenotransplantation involves risks not only to the patient, but also to larger segments of society, thus to public health in general. (ii) while most medical technologies demand assessment and risk-management at the time when the technology is sufficiently developed to be put into practice, xenotransplantation demands pro-active action at a very early stage of development. A particular challenge for any assessment of xenotransplantation is the inclusion of a satisfactory approach to the ethical issues involved."], "score": 0.98681640625}, {"id": "(Thom et al., 2023)", "paper": {"corpus_id": 265121285, "title": "Update on the ethical, legal and technical challenges of translating xenotransplantation", "year": 2023, "venue": "Journal of Medical Ethics", "authors": [{"name": "Rebecca Thom", "authorId": "2266152457"}, {"name": "D. Ayares", "authorId": "6281279"}, {"name": "David K. C. Cooper", "authorId": "2266161006"}, {"name": "John Dark", "authorId": "2299693157"}, {"name": "Sara Fovargue", "authorId": "2266152404"}, {"name": "Marie Fox", "authorId": "2266160103"}, {"name": "M. Gusmano", "authorId": "1662759024"}, {"name": "Jayme E Locke", "authorId": "2266159235"}, {"name": "Chris McGregor", "authorId": "2266151647"}, {"name": "Brendan Parent", "authorId": "34438103"}, {"name": "R. Ravanan", "authorId": "152158560"}, {"name": "D. Shaw", "authorId": "2258620328"}, {"name": "Anthony Dorling", "authorId": "2266152835"}, {"name": "Antonia J. Cronin", "authorId": "2253270241"}], "n_citations": 5}, "snippets": ["In addition to the major issues identified by Professor Gusmano and Professor Parent outlined in the previous section, during the roundtable discussion several additional ethical issues were proposed by our panel of experts and attendees. These included-ensuring equity of access to successful treatments, the burden of xenotransplantation monitoring requirements on patients, their close contacts and clinical personnel, and the need for cross border agreements to cover the prospect of recipients receiving initial treatment in one jurisdiction but moving to another."], "score": 0.98974609375}, {"id": "(Ku, 2004)", "paper": {"corpus_id": 260047382, "title": "Bioethical Issues in Xenotransplantation", "year": 2004, "venue": "Korean Journal of Medical Ethics", "authors": [{"name": "In-Hoe Ku", "authorId": "2085756759"}], "n_citations": 0}, "snippets": ["The transplantation of animal tissue and organs (xenotransplantation) is touted as one of the future options for transplantation medicine. This technology implies many unsolved practical and ethical problems.\nThe article summarizes those issues in xenotransplantation which require international efforts with special emphasis on safety regulations to prevent the transfer of pathogens from source animals to humans.\nThe most important result is the call for international guidelines, norms for reporting and compatible information technology. Means of risk assessment, risk management and risk prevention are necessary as public health tools to reduce or eliminate the risk of infection.\nThese are questions raised by patient monitoring and the implementation of archives, for example, or the economic aspects of xenotransplantation and the question of who is to bear the costs for international initiatives and public health safety mechanisms.\nThe article discusses the medical and ethical problems involved in weighing chances and risks are classified and discussed."], "score": 0.984375}, {"id": "(Shirini et al., 2025)", "paper": {"corpus_id": 276610974, "title": "Xenotransplantation Literature Update July\u2013December 2024", "year": 2025, "venue": "Xenotransplantation", "authors": [{"name": "Kasra Shirini", "authorId": "2340672108"}, {"name": "J. Ladowski", "authorId": "2261605136"}, {"name": "Raphael P. H. Meier", "authorId": "2261558306"}], "n_citations": 1}, "snippets": ["The ethical framework of xenotransplantation continues to evolve in response to societal reactions and public discourse surrounding early cases of xenotransplantation. These discussions highlighted tensions between scientific progress and societal ethical standards, underscoring the need for proactive public engagement to build trust and address normative judgments that influence societal acceptance and regulatory approaches to emerging biotechnologies [15]. The progression toward clinical xenotransplantation trials necessitates a patient selection process grounded in medical need, capacity to benefit, patient choice, and compliance to achieve ethically sound and scientifically valuable outcomes [16,17].\n\nOne of the most pressing ethical dilemmas in xenotransplantation is the selection of patients for clinical trials. Current recommendations prioritize critically ill patients who have exhausted all other therapeutic options. However, this approach has been criticized for its potential to produce unfavorable risk-benefit ratios, particularly for patients with complex medical conditions. Furthermore, concerns about justice and beneficence arise when considering acutely ill patients who may struggle to provide fully informed consent [19].\n\nIssues such as informed consent-particularly for minors-and the psychosocial impacts on patients and their families further complicate the discourse. Public perception adds another layer of difficulty, especially when determining whether adults or children should be prioritized in early clinical trials."], "score": 0.99560546875}, {"id": "(Porrett et al., 2022)", "paper": {"corpus_id": 246137465, "title": "First clinical\u2010grade porcine kidney xenotransplant using a human decedent model", "year": 2022, "venue": "American Journal of Transplantation", "authors": [{"name": "P. Porrett", "authorId": "2281019760"}, {"name": "B. Orandi", "authorId": "5991858"}, {"name": "Vineeta Kumar", "authorId": "2112231944"}, {"name": "J. Houp", "authorId": "4356984"}, {"name": "Douglas J. Anderson", "authorId": "145839206"}, {"name": "A. Cozette Killian", "authorId": "2150763884"}, {"name": "V. Hauptfeld-Dolejsek", "authorId": "1412769926"}, {"name": "Dominque E Martin", "authorId": "2150802607"}, {"name": "Sara Macedon", "authorId": "2150762884"}, {"name": "Natalie Budd", "authorId": "2150763882"}, {"name": "K. Stegner", "authorId": "151081594"}, {"name": "A. Dandro", "authorId": "8455061"}, {"name": "M. Kokkinaki", "authorId": "145327406"}, {"name": "K. Kuravi", "authorId": "50253597"}, {"name": "R. Reed", "authorId": "13203263"}, {"name": "Huma Fatima", "authorId": "2281020979"}, {"name": "J. Killian", "authorId": "3864065"}, {"name": "Gavin A. Baker", "authorId": "2055572476"}, {"name": "Jackson Perry", "authorId": "2150921660"}, {"name": "Emma D Wright", "authorId": "2151063611"}, {"name": "M. Cheung", "authorId": "12865006"}, {"name": "Elise N Erman", "authorId": "2128236479"}, {"name": "Karl Kraebber", "authorId": "119785559"}, {"name": "Tracy L. Gamblin", "authorId": "32746457"}, {"name": "Linda Guy", "authorId": "2150763789"}, {"name": "J. George", "authorId": "32335197"}, {"name": "D. Ayares", "authorId": "6281279"}, {"name": "J. Locke", "authorId": "4375801"}], "n_citations": 281}, "snippets": ["A radical solution is needed for the organ supply crisis, and the domestic pig is a promising organ source. In preparation for a clinical trial of xenotransplantation, we developed an in vivo pre\u2010clinical human model to test safety and feasibility tenets established in animal models. After performance of a novel, prospective compatible crossmatch, we performed bilateral native nephrectomies in a human brain\u2010dead decedent and subsequently transplanted two kidneys from a pig genetically engineered for human xenotransplantation. The decedent was hemodynamically stable through reperfusion, and vascular integrity was maintained despite the exposure of the xenografts to human blood pressure. No hyperacute rejection was observed, and the kidneys remained viable until termination 74 h later. No chimerism or transmission of porcine retroviruses was detected. Longitudinal biopsies revealed thrombotic microangiopathy that did not progress in severity, without evidence of cellular rejection or deposition of antibody or complement proteins. Although the xenografts produced variable amounts of urine, creatinine clearance did not recover. Whether renal recovery was impacted by the milieu of brain death and/or microvascular injury remains unknown. In summary, our study suggests that major barriers to human xenotransplantation have been surmounted and identifies where new knowledge is needed to optimize xenotransplantation outcomes in humans."], "score": 0.0}, {"id": "(Montgomery et al., 2022)", "paper": {"corpus_id": 248860025, "title": "Results of Two Cases of Pig-to-Human Kidney Xenotransplantation.", "year": 2022, "venue": "New England Journal of Medicine", "authors": [{"name": "R. Montgomery", "authorId": "50260493"}, {"name": "J. Stern", "authorId": "2057446942"}, {"name": "B. Lonze", "authorId": "6342072"}, {"name": "V. Tatapudi", "authorId": "4457075"}, {"name": "M. Mangiola", "authorId": "2261437151"}, {"name": "Ming-Hsiou Wu", "authorId": "6292806"}, {"name": "E. Weldon", "authorId": "51068768"}, {"name": "Nikki Lawson", "authorId": "1598316532"}, {"name": "Cecilia L. Deterville", "authorId": "51068511"}, {"name": "Rebecca A. Dieter", "authorId": "2126211481"}, {"name": "Brigitte Sullivan", "authorId": "2165563271"}, {"name": "Gabriella Boulton", "authorId": "2165562549"}, {"name": "Brendan Parent", "authorId": "34438103"}, {"name": "G. Piper", "authorId": "11390826"}, {"name": "Philip M. Sommer", "authorId": "50055674"}, {"name": "Samantha Cawthon", "authorId": "2165561495"}, {"name": "E. Duggan", "authorId": "83231496"}, {"name": "D. Ayares", "authorId": "6281279"}, {"name": "A. Dandro", "authorId": "8455061"}, {"name": "A. Fazio-Kroll", "authorId": "1441210826"}, {"name": "M. Kokkinaki", "authorId": "145327406"}, {"name": "L. Burdorf", "authorId": "3597021"}, {"name": "M. Lorber", "authorId": "3907877"}, {"name": "J. Boeke", "authorId": "2279453"}, {"name": "H. Pass", "authorId": "2922584"}, {"name": "B. Keating", "authorId": "2165562732"}, {"name": "A. Griesemer", "authorId": "145058641"}, {"name": "N. Ali", "authorId": "30590004"}, {"name": "S. Mehta", "authorId": "2900666"}, {"name": "Z. Stewart", "authorId": "12560126"}], "n_citations": 229}, "snippets": ["BACKGROUND\nXenografts from genetically modified pigs have become one of the most promising solutions to the dearth of human organs available for transplantation. The challenge in this model has been hyperacute rejection. To avoid this, pigs have been bred with a knockout of the alpha-1,3-galactosyltransferase gene and with subcapsular autologous thymic tissue.\n\n\nMETHODS\nWe transplanted kidneys from these genetically modified pigs into two brain-dead human recipients whose circulatory and respiratory activity was maintained on ventilators for the duration of the study. We performed serial biopsies and monitored the urine output and kinetic estimated glomerular filtration rate (eGFR) to assess renal function and xenograft rejection.\n\n\nRESULTS\nThe xenograft in both recipients began to make urine within moments after reperfusion. Over the 54-hour study, the kinetic eGFR increased from 23 ml per minute per 1.73 m2 of body-surface area before transplantation to 62 ml per minute per 1.73 m2 after transplantation in Recipient 1 and from 55 to 109 ml per minute per 1.73 m2 in Recipient 2. In both recipients, the creatinine level, which had been at a steady state, decreased after implantation of the xenograft, from 1.97 to 0.82 mg per deciliter in Recipient 1 and from 1.10 to 0.57 mg per deciliter in Recipient 2. The transplanted kidneys remained pink and well-perfused, continuing to make urine throughout the study. Biopsies that were performed at 6, 24, 48, and 54 hours revealed no signs of hyperacute or antibody-mediated rejection. Hourly urine output with the xenograft was more than double the output with the native kidneys.\n\n\nCONCLUSIONS\nGenetically modified kidney xenografts from pigs remained viable and functioning in brain-dead human recipients for 54 hours, without signs of hyperacute rejection. (Funded by Lung Biotechnology.)."], "score": 0.0}, {"id": "(Singh et al., 2022)", "paper": {"corpus_id": 252382225, "title": "The road to the first FDA\u2010approved genetically engineered pig heart transplantation into human", "year": 2022, "venue": "Xenotransplantation", "authors": [{"name": "Avneesh K. Singh", "authorId": "2109437428"}, {"name": "B. Griffith", "authorId": "2739844"}, {"name": "C. Goerlich", "authorId": "48164984"}, {"name": "D. Ayares", "authorId": "6281279"}, {"name": "M. Mohiuddin", "authorId": "2050237"}], "n_citations": 9}, "snippets": ["We have been testing genetically engineered (GE) pig hearts and optimizing immunosuppression (IS) in non\u2010human primates (NHPs) since 2005. We demonstrate how we translated this preclinical investigation into a US Food and Drug Administration (FDA)\u2010approved clinical cardiac xenotransplantation. First, genetically engineered (GE) pig hearts were transplanted into the abdomen of NHP along with IS, which included anti\u2010CD20 and anti\u2010CD40\u2010based co\u2010stimulation blockade antibodies. We reported 945 days of survival of three gene GE pig hearts in NHPs. Building on this proof\u2010of\u2010concept, we tested 3\u201310 gene\u2010modified GE pig hearts (in order to improve the immunocompatibility of the xenograft further) in a life\u2010supporting orthotopic model, but had limited success due to perioperative cardiac xenograft dysfunction (PCXD). With novel non\u2010ischemic continuous perfusion preservation (NICP), using the XVIVO Heart solution (XHS), life\u2010supporting survival was extended to 9 months. We approached the FDA under an application for \"Expanded Access\" (EA), to transplant a GE pig heart in a patient with end\u2010stage non\u2010ischemic cardiomyopathy. He was without other therapeutic options and dependent on VA\u2010ECMO. A team of FDA reviewers reviewed our preclinical research experience and data and allowed us to proceed. This clinical cardiac xenotransplantation was performed, and the patient survived for 60 days, demonstrating the translational preclinical investigation of cardiac xenotransplantation from bench to bedside. The ultimate etiology of graft failure is currently a topic of investigation and lessons learned will progress the field forward."], "score": 0.0}, {"id": "(Silverman et al., 2022)", "paper": {"corpus_id": 252874917, "title": "Reevaluating the Ethical Issues in Porcine\u2010to\u2010Human Heart Xenotransplantation", "year": 2022, "venue": "The Hastings center report", "authors": [{"name": "H. Silverman", "authorId": "2034185"}, {"name": "P. Odonkor", "authorId": "5395088"}], "n_citations": 19}, "snippets": ["The ethical issues with participation in high-risk research involving xenotransplantation are unique and require careful deliberation among the transplant investigators, psychosocial providers, psychiatrists, and ethicists. To facilitate that deliberation and ensure that the wide range of ethical issues are given due consideration, we have proposed a framework that incorporates both substantive and procedural ethical values and can be used to address pa-tient selection criteria for xenotransplant clinical trials.\n\nThe assessment of benefits and risks should ensure that a trial has significant social benefit to justify excess risks that are not justified by a compensatory potential benefit to patients. The transplant team should have a heightened sensitivity to the distributive and procedural justice concerns of psychosocial criteria used in transplant listing decisions. Efforts should be made to enhance the social support available to a patient, rather than using psychosocial criteria solely to determine the listing of potential candidates. Procuring informed and voluntary consent should represent a deliberative process that occurs over several days, with participation by a representative of the hospital's clinical ethics committee."], "score": 0.978515625}, {"id": "(Thuan et al., 2024)", "paper": {"corpus_id": 271513704, "title": "Cardiac Xenotransplantation: A Narrative Review", "year": 2024, "venue": "Reviews in cardiovascular medicine", "authors": [{"name": "P. Thuan", "authorId": "2182446680"}, {"name": "N. H. Dinh", "authorId": "2267367878"}], "n_citations": 0}, "snippets": ["As discussed in the section on Ethical and Regulatory Considerations, cXT presents numerous ethical challenges that must be effectively addressed to ensure the widespread acceptance of xenotransplantation."], "score": 0.9794921875}], "table": null}], "cost": 0.46685699999999997}}
